| 1 |
Athamneh RY, Abudalo R, Sallam M, Alqudah A, Alquran H, Amawi KF, Abu-Harirah HA. Sub-genotypes of hepatitis C virus in the Middle East and North Africa: Patterns of distribution and temporal changes. Infect Genet Evol 2023;109:105412. [PMID: 36791585 DOI: 10.1016/j.meegid.2023.105412] [Reference Citation Analysis]
|
| 2 |
Rheault M, Cousineau SE, Fox DR, Abram QH, Sagan SM. Elucidating the distinct contributions of miR-122 in the HCV life cycle reveals insights into virion assembly. Nucleic Acids Res 2023;51:2447-63. [PMID: 36807979 DOI: 10.1093/nar/gkad094] [Reference Citation Analysis]
|
| 3 |
Mohammed Mohsen S, Hussein Majeed G. Knowledge and awareness of chronic hepatitis C and liver fibrosis among health care personnel and other domains in Iraq. RB 2023;8:1-6. [DOI: 10.21931/rb/2023.08.01.35] [Reference Citation Analysis]
|
| 4 |
Ayoub N, Hatab T, Bizri AR. Challenges Facing Viral Hepatitis C Elimination in Lebanon. Pathogens 2023;12:432. [DOI: 10.3390/pathogens12030432] [Reference Citation Analysis]
|
| 5 |
Anoushiravani AA, Kalyanasundaram G, Feng JE, Congiusta F, Iorio R, DiCaprio M. Treating Hepatitis C Prior to Total Hip Arthroplasty is Cost Effective: A Markov Analysis. J Arthroplasty 2023:S0883-5403(23)00198-5. [PMID: 36878438 DOI: 10.1016/j.arth.2023.02.067] [Reference Citation Analysis]
|
| 6 |
Dilbaz N, Kuloğlu M, Evren EC, Paltun SC, Bilici R, Noyan CO, Kulaksizoglu B, Karabulut V, Umut G, Unubol B, Ucbilek E. HCV Genotype Distribution Among People Who Inject Drug in Turkey: Findings from Multicenter and Cross-Sectional Study. Subst Abuse 2023;17:11782218231157340. [PMID: 36865052 DOI: 10.1177/11782218231157340] [Reference Citation Analysis]
|
| 7 |
Hashmi AH, Farooq A, Kausar M, Husnain MA, Imran M. Genotype frequency and pattern of transmission and of Hepatitis C virus (HCV) from the Capital city and proximate areas of the Pakistan.. [DOI: 10.21203/rs.3.rs-2603615/v1] [Reference Citation Analysis]
|
| 8 |
Abdulsamad B, Afifi M, Awaad AK, Elbendary W, Mustafa H, Elsherbini B. Effect of Direct Acting Antivirals (DAAs) on Myeloid-Derived Suppressor Cells Population in Egyptian Chronic Hepatitis C Virus Patients: A Potential Immunomodulatory Role of DAAs. Viral Immunol 2023. [PMID: 36802279 DOI: 10.1089/vim.2022.0170] [Reference Citation Analysis]
|
| 9 |
Brzdęk M, Zarębska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J Gastroenterol 2023; 29(6): 949-966 [DOI: 10.3748/wjg.v29.i6.949] [Reference Citation Analysis]
|
| 10 |
Hawsawi NM, Saber T, Salama HM, Fouad WS, Hagag HM, Alhuthali HM, Eed EM, Saber T, Ismail KA, Al Qurashi HH, Altowairqi S, Samaha M, El-Hossary D. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital. Trop Med Infect Dis 2023;8. [PMID: 36828508 DOI: 10.3390/tropicalmed8020092] [Reference Citation Analysis]
|
| 11 |
Brzdęk M, Dobrowolska K, Flisiak R, Zarębska-Michaluk D. Genotype 4 hepatitis C virus-a review of a diverse genotype. Adv Med Sci 2023;68:54-9. [PMID: 36640687 DOI: 10.1016/j.advms.2022.12.003] [Reference Citation Analysis]
|
| 12 |
Foster MA, Moorman AC, Teshale EH. Hepatitis C Virus. Principles and Practice of Pediatric Infectious Diseases 2023. [DOI: 10.1016/b978-0-323-75608-2.00220-2] [Reference Citation Analysis]
|
| 13 |
孔 繁. Research Progress of Direct Antiviral Drug Therapy for Hepatitis C in Children. ACM 2023;13:140-144. [DOI: 10.12677/acm.2023.131022] [Reference Citation Analysis]
|
| 14 |
Ogawa E, Nguyen MH. Hepatitis C: epidemiology, natural history, and diagnosis. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00015-x] [Reference Citation Analysis]
|
| 15 |
Galli A, Bukh J. Mechanisms and Consequences of Genetic Variation in Hepatitis C Virus (HCV). Curr Top Microbiol Immunol 2023;439:237-64. [PMID: 36592248 DOI: 10.1007/978-3-031-15640-3_7] [Reference Citation Analysis]
|
| 16 |
Lok J, Veloz MFG, Agarwal K. Hepatitis C: treatment. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00017-3] [Reference Citation Analysis]
|
| 17 |
Patel P, Patel N, Ahmed F, Gluck J. Review of heart transplantation from hepatitis C-positive donors. World J Transplant 2022; 12(12): 394-404 [DOI: 10.5500/wjt.v12.i12.394] [Reference Citation Analysis]
|
| 18 |
Lobo MN, Irias SDF, Neto PLF, Avelino MES, da Silva Torres MK, de Carvalho Souza M, Fonseca RRS, Freitas PEB, Nunes HM, de Araújo Júnior JRR, de Brito DCN, Oliveira-Filho AB, Machado LFA. HCV-HIV Chronic Coinfection Prevalence in Amazon Region. J Clin Med 2022;11. [PMID: 36555906 DOI: 10.3390/jcm11247284] [Reference Citation Analysis]
|
| 19 |
Carey I, Christiana M, Marie-Ange M, Teresa B, Maria GV, Dusheiko G, Agarwal K. Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: Universal screening is more comprehensive. J Viral Hepat 2022;29:1079-88. [PMID: 36138559 DOI: 10.1111/jvh.13752] [Reference Citation Analysis]
|
| 20 |
McDaniel K, Utz AE, Akbashev M, Fuller KG, Boyle A, Davidson K, Marra F, Shah S, Cartwright EJ, Arora AA, DuPont S, Miller LS. Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. J Viral Hepat 2022;29:1073-8. [PMID: 36103593 DOI: 10.1111/jvh.13750] [Reference Citation Analysis]
|
| 21 |
Türkoğlu E, Parlak Z, Barut HŞ. Assessment of HCV-RNA test results and access rates to antiviral treatment in patients with anti-HCV positivity-a 10-year analysis. Turk J Med Sci 2022;52:1984-90. [PMID: 36945985 DOI: 10.55730/1300-0144.5546] [Reference Citation Analysis]
|
| 22 |
Antoniak S, Chasela CS, Freiman MJ, Stopolianska Y, Barnard T, Gandhi MM, Liulchuk M, Tsenilova Z, Viktor T, Dible J, Wose Kinge C, Akpan F, Minior T, Sigwebela N, Mohamed S, Barralon M, Marange F, Cavenaugh C, Horst CV, Antonyak S, Xulu T, Chew KW, Sanne I, Rosen S, for EQUIP Health. Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency V irus co‐infected patients in Ukraine. JGH Open 2022;6:894-903. [DOI: 10.1002/jgh3.12839] [Reference Citation Analysis]
|
| 23 |
Xiaowei Tang, Peiling Gan, Shu Huang, Xiao Pan, Ruiyu Wang, Ping Wang, Huifang Xia, Xinyi Zeng, Wensen Ren, Lei Shi, Xian Zhou, Enqiang Linghu. The scientific progress and prospects of hepatitis C research from 2013 to 2022. Am J Transl Res 2022;14. [PMID: 36505327] [Reference Citation Analysis]
|
| 24 |
Zitha T, Chen C, Mudawi H, Hussein W, Mukhtar M, Shigidi M, Yousif MEA, Ali MA, Glebe D, Kramvis A. Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis. BMC Infect Dis 2022;22:848. [DOI: 10.1186/s12879-022-07833-1] [Reference Citation Analysis]
|
| 25 |
Yakimova AV, Mukhamedshina VR, Kucherenko SG. Viral hepatitis C during pregnancy: prevalence, impact on perinatal outcomes, patient management tactics (literature review). Consilium Medicum 2022;24:477-480. [DOI: 10.26442/20751753.2022.7.201799] [Reference Citation Analysis]
|
| 26 |
Ramirez-Gonzalez LE, Camiro-Zúñiga A, Piñeirua-Menendez A, Sánchez-Avila JF, Hirata-Hernández AH, Marañón-Solorio KA, Zamora-Tapia I, Pérez-Carrizosa A, Simental-Aldaba E, Sierra-Madero JG. Risk factors associated with HCV co-infection amongst MSM and transgender women living with HIV in Mexico City: A case-control study. Ann Hepatol 2022;27:100758. [PMID: 36096295 DOI: 10.1016/j.aohep.2022.100758] [Reference Citation Analysis]
|
| 27 |
Wiznia DH, Morgan RC Jr, Gibson D. Movement is Life-Optimizing Patient Access to Total Joint Arthroplasty: HIV and Hepatitis C Disparities. J Am Acad Orthop Surg 2022;30:1011-6. [PMID: 34723921 DOI: 10.5435/JAAOS-D-21-00427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Kashnikova AD, Bystrova TN, Polyanina AV, Zalesskikh, AA. Genetic Monitoring as a Component of Hepatitis C Surveillance. PH&LE 2022. [DOI: 10.35627/2219-5238/2022-30-11-76-81] [Reference Citation Analysis]
|
| 29 |
Khedhiri M, Ghedira K, Rajhi M, Hammemi W, Sadraoui A, Touzi H, Tebibi K, Chouikha A, Triki H. Overview of the epidemic history of Hepatitis C uncommon subtypes 2i and 4d in Tunisia and in the world. Infection, Genetics and Evolution 2022;105:105375. [DOI: 10.1016/j.meegid.2022.105375] [Reference Citation Analysis]
|
| 30 |
Lohia P, Kapur S, Crane L. A Comprehensive Hepatitis C Treatment Program—An Observational Study of Collaboration Between Infectious Disease Specialists and General Internal Medicine Provider Serving a Majority Black Population. Infect Dis Clin Pract 2022;30. [DOI: 10.1097/ipc.0000000000001165] [Reference Citation Analysis]
|
| 31 |
Chou S, Yeh H, Lin T, Chang Y, Hsu H, Shen Y, Kuo T, Chen J, Chen S, Chang C. Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study. Front Immunol 2022;13:992819. [DOI: 10.3389/fimmu.2022.992819] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 32 |
Khullar S, Kiran Khatri P. COMPARATIVE ANALYSIS OF RAPID IMMUNOCHROMATOGRAPHIC TEST (ICT) AND ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) TESTS TO DETECT ANTI-HCV ANTIBODY AMONG PATIENTS UNDERGOING HAEMODIALYSIS. ijsr 2022. [DOI: 10.36106/ijsr/8205897] [Reference Citation Analysis]
|
| 33 |
Halket D, Dang J, Phadke A, Jayasekera C, Kim WR, Kwo P, Downing L, Goel A. Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study. J Gen Intern Med 2022;37:3318-24. [PMID: 35230622 DOI: 10.1007/s11606-022-07460-1] [Reference Citation Analysis]
|
| 34 |
Chen Y, Huang JC, Tsai H, Lin Y, Hsu K, Liu H. Geographic Transmission and Epidemic History of HIV-1 CRF01_AE, CRF07_BC, and HCV Subtype-6w among Taiwanese Persons Who Inject Drugs. Viruses 2022;14:2142. [DOI: 10.3390/v14102142] [Reference Citation Analysis]
|
| 35 |
Chang S, Hu H, Chen Y, Yen Y, Huang N. Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02504-6] [Reference Citation Analysis]
|
| 36 |
Mita E, Liu LJ, Shing D, Force L, Aoki K, Nakamoto D, Ishizaki A, Konishi H, Mizutani H, Ng LJ. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan. Intern Med 2022. [PMID: 36047126 DOI: 10.2169/internalmedicine.0067-22] [Reference Citation Analysis]
|
| 37 |
Dopico E, Rodriguez-Frias F, Ubillos I, Rando-Segura A, Garcia-Cehic D, Gregori J, Rando-Matos Y, Solsona L, Niubó J, Esteban JI, Costa J, Martínez MJ, Quer J. Prevalence of Hepatitis C Virus Infection, Genotypes and Subtypes in Migrants from Pakistan in Barcelona, Spain. Infect Drug Resist 2022;15:4637-44. [PMID: 36003985 DOI: 10.2147/IDR.S367715] [Reference Citation Analysis]
|
| 38 |
El Ray A, Paradis V, Montasser A, Elghannam M, Shemis M, Nessim I, Abu-taleb H, Asselah T, Mohamed A, Poté N, Akl M, Marcellin P. Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients. Egypt Liver Journal 2022;12:47. [DOI: 10.1186/s43066-022-00209-9] [Reference Citation Analysis]
|
| 39 |
Kumalo A, Teklu T, Demisse T, Anjulo A. Undiagnosed Seroprevalence of Hepatitis B and C Virus Infections in the Community of Wolaita Zone, Southern Ethiopia. Hepat Med 2022;14:111-22. [PMID: 35971532 DOI: 10.2147/HMER.S374029] [Reference Citation Analysis]
|
| 40 |
Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi MM, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew KW, van der Horst C, Tsenilova Z, Sanne I. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. BMC Infect Dis 2022;22:650. [PMID: 35896987 DOI: 10.1186/s12879-022-07615-9] [Reference Citation Analysis]
|
| 41 |
Zago D, Pozzetto I, Pacenti M, Brancaccio G, Ragolia S, Basso M, Parisi SG. Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment. TOMICROJ 2022;16:e187428582205300. [DOI: 10.2174/18742858-v16-e2205300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 42 |
Su R, Dong L, Wang Y, Sa R, Wang Y. Distribution of hepatitis C virus genotype and subtype between Mongolian and Han in Inner Mongolia. Medicine (Baltimore) 2022;101:e29545. [PMID: 35839017 DOI: 10.1097/MD.0000000000029545] [Reference Citation Analysis]
|
| 43 |
Tariq M, Shoukat AB, Akbar S, Hameed S, Naqvi MZ, Azher A, Saad M, Rizwan M, Nadeem M, Javed A, Ali A, Aziz S. Epidemiology, risk factors, and pathogenesis associated with a superbug: A comprehensive literature review on hepatitis C virus infection. SAGE Open Med 2022;10:20503121221105957. [PMID: 35795865 DOI: 10.1177/20503121221105957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022;14:1248-57. [PMID: 35978662 DOI: 10.4254/wjh.v14.i6.1248] [Reference Citation Analysis]
|
| 45 |
Zhao Z, Chu M, Guo Y, Yang S, Abudurusuli G, Frutos R, Chen T. Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives. Front Microbiol 2022;13:884598. [PMID: 35722351 DOI: 10.3389/fmicb.2022.884598] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Dietz C, Maasoumy B. Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice. Viruses 2022;14:1325. [PMID: 35746796 DOI: 10.3390/v14061325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Wanyama FM, Tauber R, Mokomba A, Nyongesa C, Blanchard V. The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya. Infect Dis Rep 2022;14:433-45. [PMID: 35735757 DOI: 10.3390/idr14030047] [Reference Citation Analysis]
|
| 48 |
Liu X, Chen Z, Tang Q, Hu P. Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China. J Virus Erad 2022;8:100071. [PMID: 35757658 DOI: 10.1016/j.jve.2022.100071] [Reference Citation Analysis]
|
| 49 |
Cabral LKD, Grisetti L, Pratama MY, Tiribelli C, Pascut D. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers (Basel) 2022;14:2700. [PMID: 35681679 DOI: 10.3390/cancers14112700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Mushtaq S, Hashmi AH, Khan A, Asad Raza Kazmi SM, Manzoor S. Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals. Front Pharmacol 2022;13:894460. [PMID: 35571102 DOI: 10.3389/fphar.2022.894460] [Reference Citation Analysis]
|
| 51 |
Mawuli G, Dzudzor B, Tachi K, Kuma AAB, Odame-Aboagye J, Obeng BM, Boateng AT, Edu-Quansah EP, Attiku KO, Agbosu E, Arjarquah A, Bonney JHK. Hepatitis C virus (HCV) infection among patients with sickle cell disease at the Korle-Bu teaching hospital. Virol J 2022;19:73. [PMID: 35459145 DOI: 10.1186/s12985-022-01797-z] [Reference Citation Analysis]
|
| 52 |
Cousineau SE, Sagan SM. The cellular poly(rC)-binding protein 2 prevents the early steps of hepatitis C virus virion assembly.. [DOI: 10.1101/2022.04.12.488029] [Reference Citation Analysis]
|
| 53 |
Khan M, Rauf W, Habib F, Rahman M, Iqbal S, Shehzad A, Iqbal M. Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease. BMC Complement Med Ther 2022;22. [DOI: 10.1186/s12906-022-03578-1] [Reference Citation Analysis]
|
| 54 |
Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A-E. Adv Ther 2022;39:1524-52. [PMID: 35220557 DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
|
| 55 |
Hussain R, Khalid H, Fatmi MQ. HCV genotype-specific drug discovery through structure-based virtual screening. Pure and Applied Chemistry 2022;0. [DOI: 10.1515/pac-2021-1104] [Reference Citation Analysis]
|
| 56 |
El-baraky I. Challenges of Hepatitis C Virus Treatment in Thalassemia. Blood - Updates on Hemodynamics and Thalassemia 2022. [DOI: 10.5772/intechopen.100123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Shahriar S, Araf Y, Ahmad R, Kattel P, Sah GS, Rahaman TI, Sadiea RZ, Sultana S, Islam MS, Zheng C, Hossain MG. Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment. Front Microbiol 2021;12:780887. [PMID: 35222296 DOI: 10.3389/fmicb.2021.780887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 58 |
Mahmud S, Chemaitelly H, Alaama AS, Hermez JG, Abu-Raddad L. Hepatitis C virus among blood donors and general population in Middle East and North Africa: Meta-analyses and meta-regressions. World J Meta-Anal 2022; 10(1): 12-24 [DOI: 10.13105/wjma.v10.i1.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 59 |
Agwa RH, Elgazzar MH, El-zayyadi IA, Saed AM, Ghannam MA, Saleh A. Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00111-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
|
| 61 |
Salas JH, Urbanowicz RA, Guest JD, Frumento N, Figueroa A, Clark KE, Keck Z, Cowton VM, Cole SJ, Patel AH, Fuerst TR, Drummer HE, Major M, Tarr AW, Ball JK, Law M, Pierce BG, Foung SKH, Bailey JR. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. Gastroenterology 2022;162:562-74. [PMID: 34655573 DOI: 10.1053/j.gastro.2021.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 62 |
Mohamed EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, Ghareeb DA, Ross B. Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients. J Viral Hepat 2022;29:147-55. [PMID: 34773341 DOI: 10.1111/jvh.13630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Yato K, Matsuda M, Watanabe N, Watashi K, Aizaki H, Kato T, Tamura K, Wakita T, Muramatsu M, Suzuki R. Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
El Raziky M, Hamdy S, Hamada Y, Abdelaziz NM, Hassany M, Doss W, Zakaria Z. Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00174-3] [Reference Citation Analysis]
|
| 65 |
Bamba M, Bordage S, Sahuc M, Moureu S, Samaillie J, Roumy V, Vauchel P, Dimitrov K, Rouillé Y, Dubuisson J, Tra Bi FH, Séron K, Sahpaz S. Anti-HCV Tannins From Plants Traditionally Used in West Africa and Extracted With Green Solvents. Front Pharmacol 2022;12:789688. [DOI: 10.3389/fphar.2021.789688] [Reference Citation Analysis]
|
| 66 |
Meshram RJ, Kathwate GH, Gacche RN. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol 2022. [PMID: 35089390 DOI: 10.1007/s00705-022-05375-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 67 |
Zhang H, Quadeer AA, McKay MR. Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a. iScience 2022;25:103569. [PMID: 34988406 DOI: 10.1016/j.isci.2021.103569] [Reference Citation Analysis]
|
| 68 |
Gibriel AA, Ismail MF, Sleem H, Zayed N, Yosry A, El-nahaas SM, Shehata NI. Diagnosis and staging of HCV associated fibrosis, cirrhosis and hepatocellular carcinoma with target identification for miR-650, 552-3p, 676-3p, 512-5p and 147b. CBM 2022. [DOI: 10.3233/cbm-210456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
Kozlowski HN, Sindhwani S, Chan WCW. The Impact of Patient Characteristics on Diagnostic Test Performance. Small Methods 2022;:e2101233. [PMID: 34994108 DOI: 10.1002/smtd.202101233] [Reference Citation Analysis]
|
| 70 |
Tunney R, Prince M, Athwal V. Chronic Hepatitis C. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_9] [Reference Citation Analysis]
|
| 71 |
Robbins M, Doucette K. Hepatitis Viruses. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_23] [Reference Citation Analysis]
|
| 72 |
Lee WJ, Foster GR. Hepatitis C. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00268-6] [Reference Citation Analysis]
|
| 73 |
Kaladhar DS, Srinivasan T. Comparative genomics and molecular epidemiology on hepatitis virus–induced hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 2022. [DOI: 10.1016/b978-0-323-98806-3.00005-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Lu W, Bai L, Chen Y. The Role of Macrophage-Derived Exosomes in Liver Diseases. Infectious Diseases & Immunity 2022;2:34-41. [DOI: 10.1097/id9.0000000000000034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 76 |
Chen XF, Zhao X, Yang Z. Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. J Med Chem 2021;64:17601-26. [PMID: 34854680 DOI: 10.1021/acs.jmedchem.1c01567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 77 |
Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci 2021;37:2014-9. [PMID: 34912436 DOI: 10.12669/pjms.37.7.4627] [Reference Citation Analysis]
|
| 78 |
Raza MN, Sughra K, Zeeshan N, Anwar MZ, Shahzad MA, Rashid U, Afroz A, Munir H. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan. Braz J Biol 2021;83:e252610. [PMID: 34909837 DOI: 10.1590/1519-6984.252610] [Reference Citation Analysis]
|
| 79 |
Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens 2021;10:1619. [PMID: 34959574 DOI: 10.3390/pathogens10121619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 80 |
Lai PC, Chen CH, Jeng LB, Yu TM, Tsai SF, Wu MJ, Cheng SB, Yang SS, Lee TY. Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection. Antimicrob Agents Chemother 2021;:AAC0200321. [PMID: 34902265 DOI: 10.1128/AAC.02003-21] [Reference Citation Analysis]
|
| 81 |
Rashid M, Ismail H. HCV extinction analysis in district Gujrat, Pakistan by using SARIMA and linear regression models. Medicine (Baltimore) 2021;100:e28193. [PMID: 34889300 DOI: 10.1097/MD.0000000000028193] [Reference Citation Analysis]
|
| 82 |
Gao Y, Nepal N, Jin SZ. Toll-like receptors and hepatitis C virus infection. Hepatobiliary Pancreat Dis Int 2021;20:521-9. [PMID: 34419367 DOI: 10.1016/j.hbpd.2021.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 83 |
Kaplan A, Brown RS. HCV and Liver Transplantation. Curr Hepatology Rep 2021;20:191-197. [DOI: 10.1007/s11901-021-00580-y] [Reference Citation Analysis]
|
| 84 |
Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Dig Liver Dis 2021;53:1603-9. [PMID: 33893040 DOI: 10.1016/j.dld.2021.03.020] [Reference Citation Analysis]
|
| 85 |
El Kassas M, Alboraie M, El-Sayed M, Elbehiry S, Sherief A, Youssef M, Moaz I, El Tahan A, Abdeen N, Eysa B, Aziz AA, Tawheed A, Ezzat S, Hassany M. Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals. Eur J Gastroenterol Hepatol 2021;33:e302-7. [PMID: 34080825 DOI: 10.1097/MEG.0000000000002043] [Reference Citation Analysis]
|
| 86 |
Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea. J Korean Med Sci 2021;36:e308. [PMID: 34845874 DOI: 10.3346/jkms.2021.36.e308] [Reference Citation Analysis]
|
| 87 |
Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021;13:1743-52. [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 88 |
Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 89 |
Ross PE, Young JR, O'Connor CM, Anoushiravani AA, DiCaprio MR. Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty. JBJS Rev 2021;9. [PMID: 34757978 DOI: 10.2106/JBJS.RVW.20.00223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 90 |
Hai T, Zou LQ. Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study. World J Clin Cases 2021; 9(31): 9417-9430 [PMID: 34877277 DOI: 10.12998/wjcc.v9.i31.9417] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 91 |
Parikh BA. Laboratory Strategies for Diagnosis and Monitoring of Hepatis C Virus Infection. Clinical Microbiology Newsletter 2021;43:193-203. [DOI: 10.1016/j.clinmicnews.2021.11.001] [Reference Citation Analysis]
|
| 92 |
Lee H, Jarhad DB, Lee A, Lee C, Jeong LS. 4′‐Selenonucleosides: Regio‐ and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti‐Hepatitis C Virus (HCV) Agents. Asian J of Organic Chemis 2021;10:2993-2999. [DOI: 10.1002/ajoc.202100563] [Reference Citation Analysis]
|
| 93 |
Mochida S, Sakuma R, Nakajima R, Kawaberi T, Izumi N. Drug use-results survey of ombitasvir/paritaprevir/ritonavir coformulated tablet in patients with genotype 1 chronic hepatitis C with or without compensated cirrhosis. Acta hepatologica Japonica 2021;62:690-702. [DOI: 10.2957/kanzo.62.690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 94 |
Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies. Glob Health Med 2021;3:276-82. [PMID: 34782869 DOI: 10.35772/ghm.2021.01075] [Reference Citation Analysis]
|
| 95 |
Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 96 |
Permanasari AA, Aoki-Utsubo C, Wahyuni TS, Tumewu L, Adianti M, Widyawaruyanti A, Hotta H, Hafid AF. An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs. BMC Complement Med Ther 2021;21:260. [PMID: 34641875 DOI: 10.1186/s12906-021-03408-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 97 |
Cooke GS, Pett S, Mccabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch’ng CL, Stone B, Wiselka M, Forton D, Mcpherson S, Halford R, Nguyen D, Smith D, Ansari MA, Ainscough H, Dennis E, Hudson F, Barnes EJ, Walker AS; the STOP-HCV trial team. Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy Mech Eval 2021;8:1-90. [DOI: 10.3310/eme08170] [Reference Citation Analysis]
|
| 98 |
Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021;13:1069-78. [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 99 |
Isakov V, Hedskog C, Wertheim JO, Hostager RE, Parhy B, Schneider AB, Suri V, Mo H, Geivandova N, Morozov V, Bessonova E, Gankina N, Zhdanov K, Abdurakhmanov D, Svarovskaia E. Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. Int J Infect Dis 2021;113:36-42. [PMID: 34560266 DOI: 10.1016/j.ijid.2021.09.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 100 |
Yilmaz B, Ruckstuhl L, Müllhaupt B, Magenta L, Kuster MH, Clerc O, Torgler R, Semmo N. Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals (Basel) 2021;14:931. [PMID: 34577631 DOI: 10.3390/ph14090931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 101 |
Danesh G, Virlogeux V, Ramière C, Charre C, Cotte L, Alizon S. Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data. PLoS Pathog 2021;17:e1009916. [PMID: 34520487 DOI: 10.1371/journal.ppat.1009916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 102 |
Di Stefano M, Ismail MH, Leitner T, Faleo G, Elmnan Adem SA, Elamin MOME, Eltreifi O, Alwazzeh MJ, Fiore JR, Santantonio TA. Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients. Viruses 2021;13:1832. [PMID: 34578414 DOI: 10.3390/v13091832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 103 |
Aisyah DN, Story A, Kremyda-vlachou M, Kozlakidis Z, Shalcross L, Hayward A. Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH study. Wellcome Open Res 2021;6:229. [DOI: 10.12688/wellcomeopenres.16907.1] [Reference Citation Analysis]
|
| 104 |
Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi M, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew K, van der Horst C, Tsenilova Z, Sanne I, for EQUIP Health. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine.. [DOI: 10.1101/2021.09.08.21263288] [Reference Citation Analysis]
|
| 105 |
Jasim SA, Ahmed NS, Mousa AA, Hmed AA, Sofy AR. Correlation between both genetic polymorphism and serum level of toll-like receptor 4 with viral load and genotype of hepatitis C virus in Iraqi patients. Gene Reports 2021;24:101287. [DOI: 10.1016/j.genrep.2021.101287] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 106 |
Hussain R, Khalid H, Fatmi MQ. Molecular Modeling Approach of Serine Protease NS3-4A Genotype 3a as a Potential Drug Target of Hepatitis C Virus: Homology Modeling and Virtual Screening Study. J Comput Biophys Chem 2021;20:631-639. [DOI: 10.1142/s273741652150037x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 107 |
Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem 2021;64:11972-89. [PMID: 34405680 DOI: 10.1021/acs.jmedchem.1c00554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 108 |
Mota Pereira F, Neves Santos FL, da Conceição Almeida Chagas M, Perez Carreiro R, Kalabric Silva L, Galvão Castro B, Rios Grassi MF. Seroprevalence and Spatial Distribution of Hepatitis C Virus in Bahia, Brazil. Am J Trop Med Hyg 2021:tpmd201615. [PMID: 34424863 DOI: 10.4269/ajtmh.20-1615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 109 |
Hashim A, Almahdi F, Albaba EA, Barkia O, Alkasam R, Almahmoud A, Nabil A, Alsulaimani A, Mosli M. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health 2020;10:178-83. [PMID: 32538035 DOI: 10.2991/jegh.k.200117.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 110 |
Chahal J, Gebert LFR, Camargo C, MacRae IJ, Sagan SM. miR-122-based therapies select for three distinct resistance mechanisms based on alterations in RNA structure. Proc Natl Acad Sci U S A 2021;118:e2103671118. [PMID: 34385308 DOI: 10.1073/pnas.2103671118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 111 |
Hartlage AS, Kapoor A. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. Viruses 2021;13:1596. [PMID: 34452460 DOI: 10.3390/v13081596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 112 |
Carman JA, Lee KK, Gardner AI, Chong SK. Hepatitis C virus infection and anaesthesia practice: A narrative review. Anaesth Intensive Care 2021;:310057X211016004. [PMID: 34378412 DOI: 10.1177/0310057X211016004] [Reference Citation Analysis]
|
| 113 |
Zhang LQ, Xu XM, Li XY, Guo J, Wang HZ, Sun JY, Cai JP. Urinary 8-oxo-7,8-dihydroguanosine levels are elevated in HCV-infected patients. Nucleosides Nucleotides Nucleic Acids 2021;:1-12. [PMID: 34379042 DOI: 10.1080/15257770.2021.1961272] [Reference Citation Analysis]
|
| 114 |
Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 115 |
Jasim SA, Ahmed NS, Mousa AA, Hmed AA, Sofy AR. Phylogenetic tree of NS5A gene of hepatitis C virus from infected Iraqi patients. Materials Today: Proceedings 2021. [DOI: 10.1016/j.matpr.2021.07.409] [Reference Citation Analysis]
|
| 116 |
Yasseen AS 3rd, Kwong JC, Feld JJ, Janjua NZ, Greenaway C, Lapointe-Shaw L, Sherman M, Mazzulli T, Kustra R, MacDonald L, Sander B, Crowcroft NS. Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver Int 2021;41:1775-88. [PMID: 33655665 DOI: 10.1111/liv.14840] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 117 |
Kitab B, Kohara M, Tsukiyama-kohara K. Host-Targeting Antivirals for Treatment of Hepatitis C. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95373] [Reference Citation Analysis]
|
| 118 |
Alghamdi S, Al-hamoudi W. Liver Transplantation and HCV Genotype 4. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95831] [Reference Citation Analysis]
|
| 119 |
Mohammed AS, Balapure A, Khan AA, Khaja MN, Ganesan R, Dutta JR. Genotyping simplified: rationally designed antisense oligonucleotide-mediated PCR amplification-free colorimetric sensing of viral RNA in HCV genotypes 1 and 3. Analyst 2021;146:4767-74. [PMID: 34231566 DOI: 10.1039/d1an00590a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 120 |
Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 121 |
Bloom DE, Khoury A, Srinivasan V. Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India. PLoS One 2021;16:e0252764. [PMID: 34292958 DOI: 10.1371/journal.pone.0252764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 122 |
Gallardo-Flores CE, Colpitts CC. Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches. Pathogens 2021;10:902. [PMID: 34358052 DOI: 10.3390/pathogens10070902] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 123 |
Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 124 |
Ullah N, Kakakhel MA, Bai Y, Xi L, Khan I, Kalra BS, Kumar T, Ahmad H, Shah M, Guanlan L, Zhang C. Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Braz J Biol 2021;83:e244977. [PMID: 34287506 DOI: 10.1590/1519-6984.244977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 125 |
Lin SK, De Maio N, Pedergnana V, Wu CH, Thézé J, Wilson DJ, Barnes E, Ansari MA. Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. Virus Evol 2021;7:veab065. [PMID: 34532064 DOI: 10.1093/ve/veab065] [Reference Citation Analysis]
|
| 126 |
Liao SH, Chen CL, Hsu CY, Chien KL, Kao JH, Chen PJ, Chen TH, Chen CH. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol 2021;75:132-41. [PMID: 33689789 DOI: 10.1016/j.jhep.2021.02.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 127 |
Bhardwaj P, Singhal E, Kumari M. PREVALENCE OF SEROPOSITIVITY IN BLOOD DONORS AT A TERTIARY CARE HOSPITAL. ijsr 2021. [DOI: 10.36106/ijsr/4500328] [Reference Citation Analysis]
|
| 128 |
Alotaibi AS, Shamas N, Ansari UU, Sanai FM, Alshahrani A, Fathelrahman AI, Aseeri MA. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia. J Pharm Bioallied Sci 2021;13:317-24. [PMID: 35017888 DOI: 10.4103/jpbs.jpbs_166_21] [Reference Citation Analysis]
|
| 129 |
Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
|
| 130 |
Young J, Wong S, Janjua NZ, Klein MB. Comparing direct acting antivirals for hepatitis C using observational data - Why and how? Pharmacol Res Perspect 2020;8:e00650. [PMID: 32894643 DOI: 10.1002/prp2.650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 131 |
Kc S, Karki N, Sharma D, Khadka S, Tiwari PS. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal. Cureus 2021;13:e15932. [PMID: 34336433 DOI: 10.7759/cureus.15932] [Reference Citation Analysis]
|
| 132 |
Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. Scientific considerations for global drug development. Sci Transl Med 2020;12:eaax2550. [PMID: 32727913 DOI: 10.1126/scitranslmed.aax2550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 133 |
Damavandi F, Wang W, Shen WZ, Cetinel S, Jordan T, Jovel J, Montemagno C, Wong GK. Enrichment of low abundance DNA/RNA by oligonucleotide-clicked iron oxide nanoparticles. Sci Rep 2021;11:13053. [PMID: 34158543 DOI: 10.1038/s41598-021-92376-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 134 |
Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 135 |
Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
|
| 136 |
Pan S, Feng K, Huang P, Zeng Y, Ke L, Yang X, Liu J, Lin C. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine (Baltimore) 2021;100:e26312. [PMID: 34128871 DOI: 10.1097/MD.0000000000026312] [Reference Citation Analysis]
|
| 137 |
Jeong S, Lee YS, Kim K, Yoon JS, Kim S, Ha J, Kang I, Choe W. 2-O-Methylhonokiol Suppresses HCV Replication via TRAF6-Mediated NF-kB Activation. Int J Mol Sci 2021;22:6499. [PMID: 34204438 DOI: 10.3390/ijms22126499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 138 |
Mousa AM, Aldebasi YH. L-carnosine mitigates interleukin-1α-induced dry eye disease in rabbits via its antioxidant, anti-inflammatory, antiapoptotic, and antifibrotic effects. Cutan Ocul Toxicol 2021;40:241-51. [PMID: 34056995 DOI: 10.1080/15569527.2021.1935995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 139 |
Sevvana M, Keck Z, Foung SK, Kuhn RJ. Structural perspectives on HCV humoral immune evasion mechanisms. Curr Opin Virol 2021;49:92-101. [PMID: 34091143 DOI: 10.1016/j.coviro.2021.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 140 |
Gantumur G, Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Lin TC, Liang PC, Liu TW, Lee JJ, Lin YC, Lin IL, Huang JF, Chuang WL, Yu ML, Tu HP, Dai CY. The association between hepatitis C virus infection and renal function. J Chin Med Assoc 2021;84:757-65. [PMID: 34074934 DOI: 10.1097/JCMA.0000000000000561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 141 |
Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 142 |
Kaddah MMY, Talaat W, El Demellawy MA. Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats. Biomed Chromatogr 2021;35:e5146. [PMID: 33893663 DOI: 10.1002/bmc.5146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 143 |
Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH. Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS One 2021;16:e0251673. [PMID: 34014997 DOI: 10.1371/journal.pone.0251673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 144 |
Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, Hammami R, Mottawea W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection. ACS Infect Dis 2021;7:1059-68. [PMID: 33119247 DOI: 10.1021/acsinfecdis.0c00432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 145 |
Ullah S, Ali M, Shaheen A, Zia F, Rahman L, Rahman S, Ali H, Din M, Waris A, Shinwari ZK. Sofosbuvir Resistance-associated Substitutions in the Palm Domain of HCV-NS5B RNA Dependent RNA Polymerase; Study of two Sofosbuvir non-responders. Int J Infect Dis 2021:S1201-9712(21)00426-4. [PMID: 34000421 DOI: 10.1016/j.ijid.2021.05.025] [Reference Citation Analysis]
|
| 146 |
Naga IS, Kamel AAF, Ooda SA, Elbab HMF, El-sharkawy RM. Effect of directly acting anti-viral agents on immunological imprints in chronic HCV-4a patients: interleukin-10 and vascular endothelial growth factor genes expression level. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00108-5] [Reference Citation Analysis]
|
| 147 |
Wang X, Wei L. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol 2021;9:419-27. [PMID: 34221928 DOI: 10.14218/JCTH.2020.00097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 148 |
Mari PC, Gulati R, Fragassi P. Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolesc Health Med Ther 2021;12:45-53. [PMID: 33994820 DOI: 10.2147/AHMT.S263864] [Reference Citation Analysis]
|
| 149 |
Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 150 |
Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 151 |
Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101596. [PMID: 33610022 DOI: 10.1016/j.clinre.2020.101596] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 152 |
Humairah I, Lukitasari L, Handajani R, Amin M, Kencono Wungu CD, Rianto E, Muhammad Ansori AN. Prevalence and Genotype Distribution of Hepatitis C Virus among Intravenous Drug users (IDUs) in Surabaya, Indonesia. RJPT 2021. [DOI: 10.52711/0974-360x.2021.00354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 153 |
Cagliani R, Mozzi A, Pontremoli C, Sironi M. Evolution and Origin of Human Viruses. Virology 2021. [DOI: 10.1002/9781119818526.ch8] [Reference Citation Analysis]
|
| 154 |
Bletsa M, Vrancken B, Gryseels S, Boonen I, Fikatas A, Li Y, Laudisoit A, Lequime S, Bryja J, Makundi R, Meheretu Y, Akaibe BD, Mbalitini SG, Van de Perre F, Van Houtte N, Těšíková J, Wollants E, Van Ranst M, Pybus OG, Drexler JF, Verheyen E, Leirs H, Gouy de Bellocq J, Lemey P. Molecular detection and genomic characterization of diverse hepaciviruses in African rodents. Virus Evol 2021;7:veab036. [PMID: 34221451 DOI: 10.1093/ve/veab036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 155 |
Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 156 |
Ahmad S, Shahid F, Tahir Ul Qamar M, Rehman HU, Abbasi SW, Sajjad W, Ismail S, Alrumaihi F, Allemailem KS, Almatroudi A, Ullah Saeed HF. Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design. Vaccines (Basel) 2021;9:293. [PMID: 33801143 DOI: 10.3390/vaccines9030293] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 157 |
Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 158 |
Antoniak S, Charles Chasela C, Freiman MJ, Stopolianska Y, Barnard T, Gandhi M, Liulchuk M, Tsenilova Z, Tretiakov V, Dible J, Kinge CW, Minior T, Mohamed S, Marange F, Cavenaugh C, van der Horst C, Antonyak S, Xulu T, Chew KW, Sanne I, Rosen S, for EQUIP Health. Treatment and Cost -outcomes of a simplified antiretroviral treatment strategy for hepatitis C among HCV and HIV co-infected patients in Ukraine.. [DOI: 10.1101/2021.03.19.21253780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 159 |
Mandoh SS, Ayman K, Elbardakheny A, Raaft H, Ibrahim AA, Alshaikh RA, Mansour FR. A cross sectional study of the risk factors of hepatitis C infection in North Egypt. Virusdisease 2021;32:22-8. [PMID: 33969153 DOI: 10.1007/s13337-020-00639-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
AlMalki WH, Shahid I, Abdalla AN, Johargy AK, Ahmed M, Hassan S. Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia. Saudi J Biol Sci 2021;28:1664-77. [PMID: 33732052 DOI: 10.1016/j.sjbs.2020.11.089] [Reference Citation Analysis]
|
| 161 |
Kawabata H, Miyake R, Asada K, Dekishima Y, Miyaike M, Kato R. Asymmetric synthesis of intermediate for (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate by desymmetrization using engineered esterase from Bacillus subtilis. J Biosci Bioeng 2021;131:599-604. [PMID: 33744099 DOI: 10.1016/j.jbiosc.2021.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 162 |
Breitinger U, Farag NS, Ali NKM, Ahmed M, El-Azizi MA, Breitinger HG. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels. J Gen Virol 2021;102. [PMID: 33709903 DOI: 10.1099/jgv.0.001571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 163 |
Ward JC, Bowyer S, Chen S, Fernandes Campos GR, Ramirez S, Bukh J, Harris M. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon. J Gen Virol 2020;101:1182-90. [PMID: 32897181 DOI: 10.1099/jgv.0.001486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 164 |
Rajhi M, Haddad-Boubaker S, Chouikha A, Bourquain D, Michel J, Hammami W, Sadraoui A, Touzi H, Ghedira K, Triki H. Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w). PLoS One 2021;16:e0248249. [PMID: 33705445 DOI: 10.1371/journal.pone.0248249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
ElDeeb MK, Ghazal AA, Metwally DE, Elghlied LA. Possible roles of methylenetetrahydrofolate reductase polymorphism and folate status in patients with early hepatitis C virus genotype 4. Arab J Gastroenterol 2021;22:121-6. [PMID: 33664006 DOI: 10.1016/j.ajg.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 166 |
Ho H, Janjua NZ, McGrail KM, Harrison M, Law MR; BC Hepatitis Testers Cohort Team. The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia. PLoS One 2021;16:e0247843. [PMID: 33647068 DOI: 10.1371/journal.pone.0247843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 167 |
Kotova VO, Balakhontseva LA, Bazykina EA, Trotsenko OE, Beldy VN, Kirdyashova SE. Genetic diversity of hepatitis C virus in Nanaian region, Khabarovsk territory. Russian Journal of Infection and Immunity 2021;11:148-156. [DOI: 10.15789/2220-7619-gdo-1265] [Reference Citation Analysis]
|
| 168 |
Qi M, Yang M, Xu L, Ma C, Huang P, Sun J, Shi J, Hu Y. Complete genome analysis identifies recombinant events and positive selection sites of hepatitis C virus from mainland China during 2010-2019. Virus Res 2021;296:198354. [PMID: 33639223 DOI: 10.1016/j.virusres.2021.198354] [Reference Citation Analysis]
|
| 169 |
Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 170 |
Ebranati E, Mancon A, Airoldi M, Renica S, Shkjezi R, Dragusha P, Della Ventura C, Ciccaglione AR, Ciccozzi M, Bino S, Tanzi E, Micheli V, Riva E, Galli M, Zehender G. Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania. Diagnostics (Basel) 2021;11:327. [PMID: 33671355 DOI: 10.3390/diagnostics11020327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 171 |
Chaabna K, Dashzeveg D, Shagdarsuren T, Al-Rifai RH. Prevalence and genotype distribution of hepatitis C virus in Mongolia: Systematic review and meta-analysis. Int J Infect Dis 2021;105:377-88. [PMID: 33601031 DOI: 10.1016/j.ijid.2021.02.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 172 |
lin S, De Maio N, Pedergnana V, Wu C, Thézé J, Barnes E, Ansari MA. Global spread and evolutionary history of HCV subtype 3a.. [DOI: 10.1101/2021.02.03.429581] [Reference Citation Analysis]
|
| 173 |
Khedhiri M, Triki H, Triki H. Hepatitis C in Tunisia from 1991 to 2019: A systematic review. Tunis Med 2021;99:189-200. [PMID: 33899186] [Reference Citation Analysis]
|
| 174 |
Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, Yu ML, Chuang WL, Huang JF. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS One 2021;16:e0246376. [PMID: 33513184 DOI: 10.1371/journal.pone.0246376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 175 |
Narayanamurthy V, Jeroish ZE, Bhuvaneshwari KS, Samsuri F. Hepatitis C virus (HCV) diagnosis via microfluidics. Anal Methods 2021;13:740-63. [PMID: 33511975 DOI: 10.1039/d0ay02045a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 176 |
Ranjbar Kermani F, Mousavi Hosseini K, Amini-kafiabad S, Maghsudlu M, Sharifi Z, Mansournia MA. Phylogenetic Analysis of NS5B Region of Hepatitis C Genotype 3a Virus among Different Risk Groups in Iran. Hepat Mon 2021;20. [DOI: 10.5812/hepatmon.108936] [Reference Citation Analysis]
|
| 177 |
Ling J, Persson Vinnersten T, Hesson JC, Bohlin J, Roligheten E, Holmes EC, Pettersson JH. Identification of hepatitis C virus in the common bed bug - a potential, but uncommon route for HCV infection? Emerg Microbes Infect 2020;9:1429-31. [PMID: 32525459 DOI: 10.1080/22221751.2020.1780950] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 178 |
Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 180 |
Bedair RN, Magour GM, Ooda SA, Amar EM, Awad AM. Could insulin receptor H1085H C > T single nucleotide polymorphism predict insulin resistance in type 2 diabetic and chronic hepatitis C virus patients in Egypt? Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-020-00066-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 181 |
Papastergiou V, Kranidioti H, Manolakopoulos S. Current Management of HCV Genotype 3 Infection. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_7] [Reference Citation Analysis]
|
| 182 |
Schwambach KH, Blatt CR. Effectiveness and potential drug interactions in antiviral therapy for the treatment of chronic hepatitis C: real-life data from a specialized center in southern Brazil. Braz J Pharm Sci 2021;57:e18746. [DOI: 10.1590/s2175-9790201900041874] [Reference Citation Analysis]
|
| 183 |
Mangia A, Piazzolla V. Current Management of Patients with HCV Genotype 2. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_6] [Reference Citation Analysis]
|
| 184 |
Chemaitelly H, Mahmud S, Mumtaz GR, Benova L, Ayoub HH, Kouyoumjian SP, Al-kanaani Z, Abu-raddad LJ. Hepatitis C Virus in the Middle East and North Africa. Handbook of Healthcare in the Arab World 2021. [DOI: 10.1007/978-3-030-36811-1_138] [Reference Citation Analysis]
|
| 185 |
Maheden K, Todd B, Gordon CJ, Tchesnokov EP, Götte M. Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. Enzymes 2021;49:315-54. [PMID: 34696837 DOI: 10.1016/bs.enz.2021.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 186 |
Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 187 |
Kapur S, Kalra N, Bhatia A, Duseja A, Das A, Dhiman RK, Chawla Y, Sandhu MS. Comparison of Elastography Point Quantification with Transient Elastography in Patients with Chronic Viral Hepatitis and Nonalcoholic Fatty Liver Disease: A Pilot Study. J Clin Exp Hepatol 2021;11:21-9. [PMID: 33679045 DOI: 10.1016/j.jceh.2020.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 188 |
Dusheiko G. Current Management of Patients with HCV Genotype 5 or 6. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_9] [Reference Citation Analysis]
|
| 189 |
Elmelodi M, Shaibani B, Ayad K. Elbasvir/grazoprevir treatment in a hemodialysis patient with hepatitis C Virus Genotype 2a Infection, not responded to sofosbuvir/daclatasvir combination therapy. Libyan J Med Sci 2021;5:132. [DOI: 10.4103/ljms.ljms_41_21] [Reference Citation Analysis]
|
| 190 |
Paraskevis D, Kostaki EG, Kramvis A, Magiorkinis G. Classification, Genetic Diversity and Global Distribution of Hepatitis C Virus (HCV) Genotypes and Subtypes. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_3] [Reference Citation Analysis]
|
| 191 |
Shaaban A, Salamah R, Elseud YA, Mohanty A, Albarrak J. Hepatocellular Carcinoma in Kuwait. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_15] [Reference Citation Analysis]
|
| 192 |
Schmitt A, Sarrazin C. Hepatitis C. Therapie-Handbuch - Gastroenterologie und Hepatologie 2021. [DOI: 10.1016/b978-3-437-23847-5.00046-6] [Reference Citation Analysis]
|
| 193 |
Karamitros T, Paraskevis D, Magiorkinis G. Hepatitis C Virus Origin. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_2] [Reference Citation Analysis]
|
| 194 |
Hemelaar J, Loganathan S, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S; WHO-UNAIDS Network for HIV Isolation and Characterization. Country Level Diversity of the HIV-1 Pandemic between 1990 and 2015. J Virol 2020;95:e01580-20. [PMID: 33087461 DOI: 10.1128/JVI.01580-20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 195 |
Audu RA, Okwuraiwe AP, Ige FA, Adeleye OO, Onyekwere CA, Lesi OA. Hepatitis C viral load and genotypes among Nigerian subjects with chronic infection and implication for patient management: a retrospective review of data. Pan Afr Med J 2020;37:335. [PMID: 33738023 DOI: 10.11604/pamj.2020.37.335.20299] [Reference Citation Analysis]
|
| 196 |
Khadempour-Arani H, Shojaeian A, Mehri-Ghahfarrokhi A, Shahraki HR, Karimi A, Dehghan A, Mobini GR. Identifying genotype profile of chronic hepatitis C infection in Southwest Iran. J Res Med Sci 2020;25:85. [PMID: 33273930 DOI: 10.4103/jrms.JRMS_524_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 197 |
Shen C, Fan H, Ge Z, Cai W, Shao J, Dong C, Xue H, Fu Z, Li J, Zhang Y, Yue M. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med (Lausanne) 2020;7:592472. [PMID: 33425940 DOI: 10.3389/fmed.2020.592472] [Reference Citation Analysis]
|
| 198 |
El-Shabrawi M, Baroudy S, Hassanin F, Behairy AS, Yakoot M, Ahmed A. Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country. Acta Paediatr 2020;109:2699-705. [PMID: 32358871 DOI: 10.1111/apa.15333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 199 |
Xu B, Deng Y, Li X, Guo S, Gao Z, Xu W, Li Y, Zhang P, Zhang L, Huang J. Development and validation of a LC-MS/MS method for simultaneous determination of TQ-A3326 and its major metabolites in human plasma, urine and feces: application to pharmacokinetic assay. Xenobiotica 2020;50:1451-60. [PMID: 32520645 DOI: 10.1080/00498254.2020.1781292] [Reference Citation Analysis]
|
| 200 |
Colomba GME, Urone N, Marco VD, Ferraro D. Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition. Viruses 2020;12:E1363. [PMID: 33260596 DOI: 10.3390/v12121363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 201 |
Khudhair HAA, Albakaa AAH, Hussein KR. Detection the Prevalence of Hepatitis C Virus among Iraqi People.. [DOI: 10.1101/2020.11.28.401968] [Reference Citation Analysis]
|
| 202 |
Wu N, Rao HY, Yang WB, Gao ZL, Yang RF, Fei R, Gao YH, Jin Q, Wei L. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl) 2020;133:253-61. [PMID: 31934936 DOI: 10.1097/CM9.0000000000000629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 203 |
Mohabati R, Rezaei R, Mohajel N, Ranjbar MM, Azadmanesh K, Roohvand F. Optimizing Consensus Generation Algorithms for Highly Variable Amino Acid Sequence Clusters.. [DOI: 10.1101/2020.11.08.373092] [Reference Citation Analysis]
|
| 204 |
Yousif MM, Ahmed H, Elsadek HM, Shendi AM, Gouda TM, Elsayed IA, Gendia MA, Magdy MM, Lbrahim NF, Sadek AMEM, Zaki AM, Shafeik H, Zahran MH. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies. J Viral Hepat 2020;27:1190-201. [PMID: 32564500 DOI: 10.1111/jvh.13349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 205 |
Fourati S, Rodriguez C, Soulier A, Donati F, Hamadat S, Poiteau L, Demontant V, Brillet R, Ahnou N, Gricourt G, Chevaliez S, Ahmed-Belkacem A, Pawlotsky JM. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Aliment Pharmacol Ther 2020;52:1583-91. [PMID: 32886807 DOI: 10.1111/apt.16054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 206 |
Mei YY, Chen YM, Wu YK, Zhang XH, Xu WX. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Can J Gastroenterol Hepatol 2020;2020:8872120. [PMID: 33194875 DOI: 10.1155/2020/8872120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 207 |
Hongjaisee S, Doungjinda N, Khamduang W, Carraway TS, Wipasa J, Debes JD, Supparatpinyo K. Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. Int J Infect Dis 2021;102:440-5. [PMID: 33130211 DOI: 10.1016/j.ijid.2020.10.082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 208 |
Yu ML, Tsai WL, Chu CJ, Kao JH. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. Kaohsiung J Med Sci 2021;37:245-52. [PMID: 33089964 DOI: 10.1002/kjm2.12317] [Reference Citation Analysis]
|
| 209 |
Ostankova YV, Valutite DE, Zueva EB, Serikova EN, Shchemelev AN, Boumbaly S, Balde TA, Semenov AV. Primary HCV Drug Resistance Mutations in Patients with Newly Diagnosed HIV Infection. Problemy Osobo Opasnykh Infektsii 2020. [DOI: 10.21055/0370-1069-2020-3-97-105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 210 |
Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
|
| 211 |
Bletsa M, Vrancken B, Gryseels S, Boonen I, Fikatas A, Li Y, Laudisoit A, Lequime S, Bryja J, Makundi R, Meheretu Y, Akaibe BD, Mbalitini SG, Van de Perre F, Van Houtte N, Těšíková J, Wollants E, Van Ranst M, Drexler JF, Verheyen E, Leirs H, de Bellocq JG, Lemey P. Unravelling the evolutionary relationships of hepaciviruses within and across rodent hosts.. [DOI: 10.1101/2020.10.09.332932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 212 |
Namayandeh M, Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. Microbiol Immunol 2020;64:762-7. [PMID: 32902892 DOI: 10.1111/1348-0421.12845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 213 |
Chopra D, Bhandari B. Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment? Infect Disord Drug Targets 2020;20:2-15. [PMID: 30113002 DOI: 10.2174/1871526518666180816101124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 214 |
Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients. Infect Disord Drug Targets 2020;20:43-8. [PMID: 30009715 DOI: 10.2174/1871526518666180716141806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 215 |
Nguyen D, Smith D, Vaughan-Jackson A, Magri A, Barnes E, Simmonds P; STOP-HCV Consortium. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. J Hepatol 2020;73:794-9. [PMID: 32470499 DOI: 10.1016/j.jhep.2020.05.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 216 |
Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Nguyen T, Hung Le M, Pham TT, Mensa F, Asselah T. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver Int 2020;40:2385-93. [PMID: 32445613 DOI: 10.1111/liv.14535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 217 |
Shen M, Shen Y, Fan X, Men R, Ye T, Yang L. Roles of Macrophages and Exosomes in Liver Diseases. Front Med (Lausanne) 2020;7:583691. [PMID: 33072790 DOI: 10.3389/fmed.2020.583691] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 218 |
Yip CCY, Sridhar S, Lau JHN, Cheng AKW, Leung KH, Chen JHK, Chan KH, Cheng VCC, Yuen KY. Comparative performance of two commercial sample-to-result systems for hepatitis C virus quantitation and genotyping. Expert Rev Mol Diagn 2020;20:1253-8. [PMID: 32893699 DOI: 10.1080/14737159.2020.1820327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 219 |
Mundim AEFM, de Castro FOF, Albuquerque MBB, Vilanova-Costa CAST, Pfrimer IAH, Silva AMTC. Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic review. Virusdisease 2020;31:220-8. [PMID: 32904849 DOI: 10.1007/s13337-020-00616-9] [Reference Citation Analysis]
|
| 220 |
Phillips M, Abboud J, Abodunde B, Paul DP 3rd, Coustasse A. The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia. Health Care Manag (Frederick) 2020;39:2-11. [PMID: 31876587 DOI: 10.1097/HCM.0000000000000278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 221 |
Ikram S, Ahmad J, Rehman IU, Durdagi S. Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain. J Mol Graph Model 2020;101:107727. [PMID: 33027738 DOI: 10.1016/j.jmgm.2020.107727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 222 |
Zheng YX, Ma SJ, Xiong YH, Fan XG. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis. J Gastroenterol Hepatol 2020;35:1477-87. [PMID: 32246857 DOI: 10.1111/jgh.15051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 223 |
Amougou-Atsama M, Jean Adrien Atangana P, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. J Viral Hepat 2020;27:880-5. [PMID: 32301239 DOI: 10.1111/jvh.13303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 224 |
Oluremi AS, Opaleye OO, Ogbolu DO, Alli OAT, Adeola O, Alaka O, Ogunleke OA, Ojo A, Bello MD, Enitan SS, Adediji IO, Adelakun AA, Suleiman IE. High Viral Hepatitis Infection among Pregnant Women Attending Antenatal Clinic in Adeoyo Maternity Teaching Hospital Ibadan (AMTHI) Oyo State, Nigeria. J Immunoassay Immunochem 2020;41:913-23. [PMID: 32835616 DOI: 10.1080/15321819.2020.1807358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 225 |
El-Sayed M, Abdellatif Z, Elsharkawy A, El Kassas M, Abd Elmoniem R, Marzouk A, Fouad R, Esmat G, Abdel Alem S. Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection 2020;48:913-22. [PMID: 32816249 DOI: 10.1007/s15010-020-01505-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 226 |
Mahmoudvand S, Shokri S, Azaran A, Seyedian SS, Makvandi M, Mirzaei H, Sheikhrobat SB. Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study. Ther Apher Dial 2021;25:218-24. [PMID: 32510846 DOI: 10.1111/1744-9987.13535] [Reference Citation Analysis]
|
| 227 |
Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience. Ann Hepatol 2019;18:450-5. [PMID: 31028014 DOI: 10.1016/j.aohep.2018.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 228 |
Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Ann Hepatol 2019;18:434-8. [PMID: 31023614 DOI: 10.1016/j.aohep.2018.09.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 229 |
Kato N. Hepatitis C virus (HCV)：Diversity and variation of RNA genome. Okayama I Z 2020;132:60-67. [DOI: 10.4044/joma.132.60] [Reference Citation Analysis]
|
| 230 |
Kim K, Lee YS, Jeong S, Kim D, Chon S, Pak YK, Kim S, Ha J, Kang I, Choe W. A Small Molecule, 4-Phenylbutyric Acid, Suppresses HCV Replication via Epigenetically Induced Hepatic Hepcidin. Int J Mol Sci 2020;21:E5516. [PMID: 32752233 DOI: 10.3390/ijms21155516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 231 |
Castro GLC, Amoras EDGS, Araújo MSM, Conde SRSDS, Vallinoto ACR. Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil. Braz J Infect Dis 2020;24:304-9. [PMID: 32735876 DOI: 10.1016/j.bjid.2020.06.010] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 232 |
Pereira FM, Almeida MDCC, Santos FLN, Carreiro RP, Galvão-Castro B, Grassi MFR. Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil. PLoS One 2020;15:e0223087. [PMID: 32692782 DOI: 10.1371/journal.pone.0223087] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 233 |
Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver Int 2020. [PMID: 32640072 DOI: 10.1111/liv.14591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 234 |
Musa NI, Mohamed IE, Abohalima AS. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00035-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 235 |
Donnison T, von Delft A, Brown A, Swadling L, Hutchings C, Hanke T, Chinnakannan S, Barnes E. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine 2020;38:5036-48. [PMID: 32532545 DOI: 10.1016/j.vaccine.2020.05.042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 236 |
Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction 2020;115:1244-62. [PMID: 32009283 DOI: 10.1111/add.14944] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 237 |
El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J 2020;72:37. [PMID: 32613565 DOI: 10.1186/s43044-020-00070-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 238 |
Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 239 |
Tung HD, Lee PL, Chen JJ, Kuo HT, Sheu MJ, Cheng CT, Chuang TW, Kao HJ, Hou CY, Tsai HH, Wu LC, Lee C. Geographic variation of genotype 6 hepatitis C virus infection in an endemic area of southern Taiwan. J Formos Med Assoc 2020;119:1876-80. [PMID: 32620462 DOI: 10.1016/j.jfma.2020.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 240 |
Nie B, Guo Y, Zhang K, Liu J, Yun S. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China. Arch Virol 2020;165:2013-20. [PMID: 32601956 DOI: 10.1007/s00705-020-04713-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 241 |
Nakamura H, Fujioka S, Terui T, Okuda S, Kondo K, Tamatani Y, Akagi Y, Komoda Y, Kinoshita W, Ito S, Maeda K, Ukaji Y, Inaba T. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. Bioorg Med Chem Lett 2020;30:127361. [PMID: 32738974 DOI: 10.1016/j.bmcl.2020.127361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 242 |
Hassany SM, Hassan W, Abo-Alam H, Khalaf M, Nafeh AM, Nasr-Eldin E, Mostafa EF. Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed. Infect Drug Resist 2020;13:1873-80. [PMID: 32606836 DOI: 10.2147/IDR.S241948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 243 |
Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, Holst PJ, Bassi MR, Stornaiuolo M, Mori F, Vassilev V, Li W, Donnison T, Gentile C, Turner B, von Delft A, Del Sorbo M, Barra F, Contino AM, Abbate A, Novellino E, Thomsen AR, Christensen JP, Lahm A, Grazioli F, Ammendola V, Siani L, Colloca S, Klenerman P, Nicosia A, Dorrell L, Folgori A, Capone S, Barnes E; PEACHI Consortium. MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. Sci Transl Med 2020;12. [PMID: 32554708 DOI: 10.1126/scitranslmed.aaz7715] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 244 |
Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines (Basel) 2020;8:E294. [PMID: 32532076 DOI: 10.3390/vaccines8020294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 245 |
Fadl N, Salem TZ. Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. Rev Med Virol 2020;30:e2120. [PMID: 32478480 DOI: 10.1002/rmv.2120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 246 |
Lepage C, Garber G, Corrin R, Galanakis C, Leonard L, Cooper C. Telemedicine successfully engages marginalized rural hepatitis C patients in curative care. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2020;5:87-97. [DOI: 10.3138/jammi-2019-0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 247 |
Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
|
| 248 |
Cheng H, Xu C, Zhang D, Zhang Z, Liu J, Lv X. Multiclass identification of hepatitis C based on serum Raman spectroscopy. Photodiagnosis Photodyn Ther 2020;30:101735. [PMID: 32171878 DOI: 10.1016/j.pdpdt.2020.101735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 249 |
Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 250 |
Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, Day J, Rahman M, Le HM. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS One 2020;15:e0233446. [PMID: 32433676 DOI: 10.1371/journal.pone.0233446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 251 |
Warkad SD, Nimse SB, Song KS, Kim T. Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes. ACS Omega 2020;5:10794-9. [PMID: 32455199 DOI: 10.1021/acsomega.0c00386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 252 |
McCabe L, White IR, Chau NVV, Barnes E, Pett SL, Cooke GS, Walker AS; SEARCH investigators. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. Trials 2020;21:413. [PMID: 32423467 DOI: 10.1186/s13063-020-04350-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 253 |
Yamamoto C, Nagashima S, Chuon C, Ko K, Huy Do S, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, Tanaka J. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia. Viruses 2020;12:E551. [PMID: 32429467 DOI: 10.3390/v12050551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 254 |
Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 255 |
Alberione MP, Moeller R, Kirui J, Ginkel C, Doepke M, Ströh LJ, Machtens JP, Pietschmann T, Gerold G. Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Med Microbiol Immunol 2020;209:499-514. [PMID: 32322956 DOI: 10.1007/s00430-020-00675-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 256 |
Chen P, Zheng Y, Cai Y, Zou P, Li N, Peng C, Gao H, Liu J, Chen Y, Tong Z, Li L. Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study. Can J Gastroenterol Hepatol 2020;2020:8219536. [PMID: 32377514 DOI: 10.1155/2020/8219536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 257 |
El-Bendary M, Neamatallah M, Elalfy H, Besheer T, Kamel E, Mousa H, Eladl AH, El-Setouhy M, El-Gilany AH, El-Waseef A, Esmat G. HLA Class II-DRB1 Alleles with Hepatitis C Virus Infection Outcome in Egypt: A Multicentre Family-based Study. Ann Hepatol 2019;18:68-77. [PMID: 31113612 DOI: 10.5604/01.3001.0012.7864] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 258 |
Gayam V, Gill A, Garlapati P, Mohanty S. Direct-Acting Antivirals in Chronic Hepatitis C Infection with Liver Cirrhosis. Hepatitis B and C 2020. [DOI: 10.5772/intechopen.83609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 259 |
Thom Shawa I. Hepatitis B and C Viruses. Hepatitis B and C 2020. [DOI: 10.5772/intechopen.82772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 260 |
Kyuregyan KK, Kichatova VS, Karlsen AA, Isaeva OV, Solonin SA, Petkov S, Nielsen M, Isaguliants MG, Mikhailov MI. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines 2020;8:E80. [PMID: 32272736 DOI: 10.3390/biomedicines8040080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 261 |
Behairy BE, El-Araby HA, El-Guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. J Pediatr 2020;219:106-10. [PMID: 32008767 DOI: 10.1016/j.jpeds.2019.12.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 262 |
Sun W, Du Y, Li X, Du B. Rapid and Sensitive Detection of Hepatitis C Virus in Clinical Blood Samples Using Reverse Transcriptase Polymerase Spiral Reaction. J Microbiol Biotechnol 2020;30:459-68. [PMID: 31893596 DOI: 10.4014/jmb.1910.10041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 263 |
Zhang D, Zhang X, Xu L, Tyrrell DL, Houghton M, Ba-thein W. Seroepidemiology of Hepatitis C Among Drug Users at a Detoxification Center in Southeast China. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.99249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 264 |
Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 265 |
Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020;4:577-587. [PMID: 32258952 DOI: 10.1002/hep4.1491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 266 |
Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 267 |
Tatar B, Köse Ş, Ergun NC, Turken M, Onlen Y, Yılmaz Y, Akhan S. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. Rev Assoc Med Bras (1992) 2019;65:1470-5. [PMID: 31994628 DOI: 10.1590/1806-9282.65.12.1470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 268 |
Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt Yilmaz N, Schiffer CA. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. ACS Chem Biol 2020;15:342-52. [PMID: 31868341 DOI: 10.1021/acschembio.9b00675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 269 |
Ramirez S, Fernandez-Antunez C, Mikkelsen LS, Pedersen J, Li YP, Bukh J. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Antimicrob Agents Chemother 2020;64:e01888-19. [PMID: 31818814 DOI: 10.1128/AAC.01888-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 270 |
Babaei AH, Safarpour AR, Fattahi MR, Ahmadi V. Epidemiology of Hepatitis C Virus Infection Among 1,959 Patients in Shiraz, Southern Iran, Between 1991 and 2016. Arch Clin Infect Dis 2020;15. [DOI: 10.5812/archcid.98849] [Reference Citation Analysis]
|
| 271 |
Li H, Yang Z, Zhang S, Xu L, Wei Y, Jiang J, Caro L, Feng HP, McCrea JB, Li M, Xie S, Wang J, Zhao XM, Mu S. A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants. Clin Pharmacol 2020;12:1-11. [PMID: 32104104 DOI: 10.2147/CPAA.S224662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 272 |
Li X, Li J, Feng Y, Cai H, Li YP, Peng T. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Antiviral Res. 2020;177:104734. [PMID: 32057770 DOI: 10.1016/j.antiviral.2020.104734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 273 |
Ibrahim MG, Sharafeldin AA, Mousa NI, Mousa TK, El Missiri AM. Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection. Egypt Heart J 2020;72:7. [PMID: 32030482 DOI: 10.1186/s43044-020-0042-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 274 |
Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Eur J Hosp Pharm 2020;27:e41-7. [PMID: 32296504 DOI: 10.1136/ejhpharm-2019-002060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 275 |
Gummow J, Masavuli MG, Mekonnen ZA, Li Y, Wijesundara DK, Shrestha AC, Voskoboinik I, Gowans EJ, Grubor-Bauk B. Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. Vaccines (Basel) 2020;8:E53. [PMID: 32013228 DOI: 10.3390/vaccines8010053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 276 |
Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 277 |
Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 278 |
Chris Krueger A, Chen HJ, Randolph JT, Brown BS, Halvorsen GT, Heyman HR, Li T, Marvin CC, Shanley JP, Voight EA, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin ML, Krishnan P, Henry RF, Wagner R, DeGoey DA. Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus. Bioorg Med Chem 2020;28:115208. [PMID: 31740203 DOI: 10.1016/j.bmc.2019.115208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 279 |
Kanto T, Yoshio S. Hepatitis C. Liver Immunology 2020. [DOI: 10.1007/978-3-030-51709-0_17] [Reference Citation Analysis]
|
| 280 |
Madhav A, Will RC, Mutreja A. The Evolution of Microbial Defence Systems Against Antimicrobial Agents. Antimicrobial Resistance 2020. [DOI: 10.1007/978-981-15-3658-8_1] [Reference Citation Analysis]
|
| 281 |
Comar M, De Seta F, Zanotta N, Del Bue S, Ferrante P. New Diagnostic Approaches to Viral Sexually Transmitted Infections. Sexually Transmitted Infections 2020. [DOI: 10.1007/978-3-030-02200-6_6] [Reference Citation Analysis]
|
| 282 |
Maurya V, Khullar S, Parihar R, Khatri P. Seroprevalence of hepatitis B virus and hepatitis C virus infection in haemodialysis patients at tertiary care hospital in Western Rajasthan, India. J Acad Clin Microbiol 2020;22:23. [DOI: 10.4103/jacm.jacm_38_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 283 |
Mandhwani R, Hanif FM, Lail G, Luck NH, Khalid MA, Ul Haque MM, Laeeq SM, Aziz T. Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. Gastroenterol Hepatol Bed Bench 2020;13:141-6. [PMID: 32308935] [Reference Citation Analysis]
|
| 284 |
Kamthong A, Biological Engineering Program, Faculty of Engineering, King Mongkut’s University of Technology Thonburi, Bangkok 10140, Thailand, Boonyalekha P, Leelawattanachai J, Dujduan W. Application of the Synthetic Escherichia coli’s Twin-Arginine Translocation Pathway for the Detection of Intracellular Antibodies against Hepatitis C Viral Protease. IJBBB 2020;10:49-57. [DOI: 10.17706/ijbbb.2020.10.1.49-57] [Reference Citation Analysis]
|
| 285 |
Rossotti R, Puoti M. Sexually Transmitted Hepatitis. Sexually Transmitted Infections 2020. [DOI: 10.1007/978-3-030-02200-6_13] [Reference Citation Analysis]
|
| 286 |
Gorka S, Gulzar GM, Yattoo GN, Sodhi JS, Dar GA, Laway MA, Kaushik S, Dhar N, Mushfiq S, Aziz RA. Genotype 1 and 3 Response to Velpatasvir and Sofosbuvir in Chronic Hepatitis C in the Kashmiri Population: An Observational Study. J Clin Exp Hepatol 2020;10:155-62. [PMID: 32189931 DOI: 10.1016/j.jceh.2019.07.003] [Reference Citation Analysis]
|
| 287 |
Öz S, Köroğlu M, Özbek A, Demiray T, Karabay O, Trak G, Altindiş M. Sakarya İlinde Hepatit C Virüs Genotip Dağılımı; Üç Yıllık Retrospektif Çalışma. Online Türk Sağlık Bilimleri Dergisi 2019. [DOI: 10.26453/otjhs.480164] [Reference Citation Analysis]
|
| 288 |
Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]
|
| 289 |
Shin S, Kang J, Kang J, Seo YI, Park JR, Lee DD, Min H, Kim M. Analysis of HCV RNA Genotypes and Quantitative Values of Korean HCV NAT Reactive Blood Donors. KJBT 2019;30:205-211. [DOI: 10.17945/kjbt.2019.30.3.205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 290 |
Nakamura H, Akagi Y, Terui T, Fujioka S, Komoda Y, Kinoshita W, Maeda K, Ukaji Y, Inaba T. Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity. Bioorg Med Chem Lett 2020;30:126932. [PMID: 31952964 DOI: 10.1016/j.bmcl.2019.126932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 291 |
Cink RD, Lukin KA, Bishop RD, Zhao G, Pelc MJ, Towne TB, Gates BD, Ravn MM, Hill DR, Ding C, Cullen SC, Mei J, Leanna MR, Henle J, Napolitano JG, Nere NK, Chen S, Sheikh A, Kallemeyn JM. Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis. Org Process Res Dev 2020;24:183-200. [DOI: 10.1021/acs.oprd.9b00469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 292 |
El-Maraghy SA, Adel O, Zayed N, Yosry A, El-Nahaas SM, Gibriel AA. Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis. J Adv Res 2020;22:57-66. [PMID: 31956442 DOI: 10.1016/j.jare.2019.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 293 |
Altunçekiç Yildirim A, Cırrık S, Çetinkol Y, Çalgın MK, Noyan T. Are serum GRP78 levels significant in chronic hepatitis C patients? A case-control study. Journal of Surgery and Medicine 2019. [DOI: 10.28982/josam.595537] [Reference Citation Analysis]
|
| 294 |
Watanabe N, Suzuki T, Date T, Hussan HA, Hmwe SS, Aizaki H, Sugiyama M, Mizokami M, Delaney Iv W, Cheng G, Muramatsu M, Wakita T. Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. J Gen Virol 2020;101:188-97. [PMID: 31859613 DOI: 10.1099/jgv.0.001378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 295 |
Kim HS, You Y, Mun J, Gadhe CG, Moon H, Lee JS, Pae AN, Kohara M, Keum G, Kim BM, Jang SK. Structure-activity relationships of fluorene compounds inhibiting HCV variants. Antiviral Res 2020;174:104678. [PMID: 31862501 DOI: 10.1016/j.antiviral.2019.104678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 296 |
Rehm J, Shield KD. Global Burden of Alcohol Use Disorders and Alcohol Liver Disease. Biomedicines 2019;7:E99. [PMID: 31847084 DOI: 10.3390/biomedicines7040099] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 297 |
Gallego P, Rojas Á, Falcón G, Carbonero P, García-Lozano MR, Gil A, Grande L, Cremades O, Romero-Gómez M, Bautista JD, Del Campo JA. Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication. Food Funct 2019;10:3758-67. [PMID: 31179460 DOI: 10.1039/c9fo00733d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 298 |
Ohya K, Kawaoka T, Imamura M, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Chayama K. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. Intern Med. 2020;59:941-944. [PMID: 31813916 DOI: 10.2169/internalmedicine.3824-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 299 |
Chahal J, Gebert LFR, Gan HH, Camacho E, Gunsalus KC, MacRae IJ, Sagan SM. miR-122 and Ago interactions with the HCV genome alter the structure of the viral 5' terminus. Nucleic Acids Res. 2019;47:5307-5324. [PMID: 30941417 DOI: 10.1093/nar/gkz194] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 300 |
Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 301 |
Ramdas V, Talwar R, Banerjee M, Joshi AA, Das AK, Walke DS, Borhade P, Dhayagude U, Loriya R, Gote G, Bommakanti A, Sivaram A, Agarwal G, Goswami A, Nigade P, Mehta M, Patil V, Modi D, Kumar H, Mallurwar S, Dash A, Modi F, Kuldharan S, Srivastava P, Singh M, Narasimham L, Gundu J, Sharma S, Kamboj RK, Palle VP. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem 2019;62:10563-82. [PMID: 31710479 DOI: 10.1021/acs.jmedchem.9b01562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 302 |
Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother 2020;121:109657. [PMID: 31810127 DOI: 10.1016/j.biopha.2019.109657] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 303 |
Lemoine L, Segarra-newnham M. Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection. Ann Clin Gastroenterol Hepatol 2019;3:027-030. [DOI: 10.29328/journal.acgh.1001011] [Reference Citation Analysis]
|
| 304 |
Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019;14:e0225061. [PMID: 31714950 DOI: 10.1371/journal.pone.0225061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 305 |
Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int 2019;2019:2301291. [PMID: 31815126 DOI: 10.1155/2019/2301291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 306 |
Morales JM, Sawinski D. New insights into the rational use of HCV+ organs worldwide. Clin Transplant 2019;33:e13739. [PMID: 31648391 DOI: 10.1111/ctr.13739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 307 |
Dawood RM, Moustafa RI, Abdelhafez TH, El-Shenawy R, El-Abd Y, Bader El Din NG, Dubuisson J, El Awady MK. A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. BMC Infect Dis 2019;19:932. [PMID: 31690267 DOI: 10.1186/s12879-019-4571-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 308 |
Spitz N, Barros JJ, do Ó KM, Brandão-Mello CE, Araujo NM. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. Viruses 2019;11:E1000. [PMID: 31683566 DOI: 10.3390/v11111000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 309 |
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67:1010-1017. [PMID: 29566246 DOI: 10.1093/cid/ciy220] [Cited by in Crossref: 86] [Cited by in F6Publishing: 98] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 310 |
Lee H, Jarhad DB, Yu J, Lee C, Jeong LS. Asymmetric Synthesis of 2'-C-Methyl-4'-selenonucleosides as Anti-Hepatitis C Virus Agents. J Org Chem 2019;84:14414-26. [PMID: 31608633 DOI: 10.1021/acs.joc.9b01462] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 311 |
Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. J Virol 2019;93:e00810-19. [PMID: 31462563 DOI: 10.1128/JVI.00810-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 312 |
Serdari D, Kostaki EG, Paraskevis D, Stamatakis A, Kapli P. Automated, phylogeny-based genotype delimitation of the Hepatitis Viruses HBV and HCV. PeerJ 2019;7:e7754. [PMID: 31667012 DOI: 10.7717/peerj.7754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 313 |
Cagliani R, Forni D, Sironi M. Mode and tempo of human hepatitis virus evolution. Comput Struct Biotechnol J 2019;17:1384-95. [PMID: 31768229 DOI: 10.1016/j.csbj.2019.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 314 |
Naz Z, Wahid B, Usman S, Saleem K, Rafique S, Ali A, Idrees M. Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. J Interferon Cytokine Res 2018;38:255-60. [PMID: 29920131 DOI: 10.1089/jir.2017.0138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 315 |
Matsumoto J, San SN, Fujiyoshi M, Kawauchi A, Chiba N, Tagai R, Sanbe R, Yanaka S, Sakaue H, Kato Y, Nakamura H, Yamada H, Ariyoshi N. Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. J Hum Genet 2020;65:143-53. [PMID: 31645655 DOI: 10.1038/s10038-019-0685-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 316 |
McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 317 |
Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet 2019;394:1451-66. [PMID: 31631857 DOI: 10.1016/S0140-6736(19)32320-7] [Cited by in Crossref: 220] [Cited by in F6Publishing: 201] [Article Influence: 55.0] [Reference Citation Analysis]
|
| 318 |
Pedersen MS, Mollerup S, Nielsen LG, Jenssen H, Bukh J, Schønning K. Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle. Microbiol Resour Announc 2019;8:e01030-19. [PMID: 31624172 DOI: 10.1128/MRA.01030-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 319 |
Mahmud S, Chemaitelly HS, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Key associations for hepatitis C virus genotypes in the Middle East and North Africa. J Med Virol 2020;92:386-93. [PMID: 31663611 DOI: 10.1002/jmv.25614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 320 |
Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 321 |
El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 322 |
. UEG Week 2019 Poster Presentations. United European Gastroenterol J 2019;7:189-1030. [PMID: 32213001 DOI: 10.1177/2050640619854671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 323 |
Khan MA, Khan SA, Hamayun M, Ali M, Idrees M. Sequence variability of HCV 3a isolates based on core gene in patients from Lahore, Pakistan. Future Virology 2019;14:641-53. [DOI: 10.2217/fvl-2019-0086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 324 |
Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, Shah ZH, Ahmed H, Afzal MS. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. Viral Immunol 2019;32:402-13. [PMID: 31556811 DOI: 10.1089/vim.2019.0058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 325 |
Moghimi M, Tavakoli F, Doosti M, Ahmadi-Vasmehjani A, Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res Notes 2019;12:626. [PMID: 31551080 DOI: 10.1186/s13104-019-4651-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 326 |
Guo M, Lu J, Gan T, Xiang X, Xu Y, Xie Q, Zhong J. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. Antiviral Res 2019;171:104612. [PMID: 31542377 DOI: 10.1016/j.antiviral.2019.104612] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 327 |
Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 328 |
Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Lancet Infect Dis 2019;19:1255-63. [PMID: 31540840 DOI: 10.1016/S1473-3099(19)30264-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 329 |
Pereira FM, Almeida MDCCD, Santos FLN, Carreiro RP, Galvão-castro B, Grassi MFR. Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil.. [DOI: 10.1101/771360] [Reference Citation Analysis]
|
| 330 |
Asante-Appiah E, Ingravallo P, McMonagle P, Bystol K, Xia E, Curry S, Qiu P, Black S, Chase R, Liu R, Lahser F. Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527040 DOI: 10.1128/AAC.01269-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 331 |
Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis 2019;19:809. [PMID: 31521121 DOI: 10.1186/s12879-019-4403-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 332 |
Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. J Clin Pharmacol 2020;60:331-9. [PMID: 31515816 DOI: 10.1002/jcph.1524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 333 |
Abdelfattah SN, Haseeb AF, Tawfik MM, Khalil DM, Attia D. Soluble CD25 as a predictor of hepatocellular carcinoma compared with alpha-fetoprotein. Clin Exp Hepatol 2019;5:140-6. [PMID: 31501790 DOI: 10.5114/ceh.2019.85165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 334 |
Hayes CN, Imamura M, Chayama K. Management of HCV patients in cases of direct-acting antiviral failure. Expert Rev Gastroenterol Hepatol 2019;13:839-48. [PMID: 31392907 DOI: 10.1080/17474124.2019.1651642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 335 |
Morales-Arraez D, Alonso-Larruga A, Diaz-Flores F, García Dopico JA, de Vera A, Quintero E, Hernández-Guerra M. Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. J Viral Hepat 2019;26:1117-23. [PMID: 31077515 DOI: 10.1111/jvh.13122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 336 |
Lin WY, Lin MS, Weng YH, Yeh TH, Lin YS, Fong PY, Wu YR, Lu CS, Chen RS, Huang YZ. Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection. JAMA Neurol 2019;76:1019-27. [PMID: 31168563 DOI: 10.1001/jamaneurol.2019.1368] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 337 |
Ul Abideen Z, Siddique S, Nasrullah I, Khan JS, Rehman S, Tong Y, Qamar R, Butt AM. A 2-year retrospective study of viral and host-associated risk factors in Pakistani hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol 2019;31:1103-9. [PMID: 30829691 DOI: 10.1097/MEG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 338 |
Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O. The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scand J Gastroenterol 2019;54:1172-5. [PMID: 31479286 DOI: 10.1080/00365521.2019.1643403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 339 |
Schrier L, Wyder C, del Torso S, Stiris T, von Both U, Brandenberger J, Ritz N. Medical care for migrant children in Europe: a practical recommendation for first and follow-up appointments. Eur J Pediatr 2019;178:1449-1467. [DOI: 10.1007/s00431-019-03405-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 340 |
Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 341 |
Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019;14:e0221231. [PMID: 31469856 DOI: 10.1371/journal.pone.0221231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 342 |
Patra T, Sasaki R, Meyer K, Ray RB, Ray R. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections. J Virol 2019;93:e00811-19. [PMID: 31243135 DOI: 10.1128/JVI.00811-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 343 |
Ng M, Hayashi K, Voon P, Shulha HP, DeBeck K, Milloy MJ, Ti L. Characterising the association between positive hepatitis C virus antibody and pain among people who inject drugs. Drug Alcohol Rev 2019;38:639-43. [PMID: 31418953 DOI: 10.1111/dar.12969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 344 |
Ren J, Ojeda I, Patel M, Johnson ME, Lee H. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorg Med Chem Lett 2019;29:2349-53. [PMID: 31201062 DOI: 10.1016/j.bmcl.2019.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 345 |
Ghazy AA, Osman EM, Rashwan EA, Gaballah AH, Mostafa H, Tawfik S. Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients. J Med Virol 2019;91:2166-73. [PMID: 31368531 DOI: 10.1002/jmv.25559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 346 |
Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Hepatitis C infection: Updates on treatment guidelines. Nurse Pract 2017;42:14-23. [PMID: 28379888 DOI: 10.1097/01.NPR.0000515423.38284.28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 347 |
Caspi DD, Cink RD, Clyne D, Diwan M, Engstrom KM, Grieme T, Mei J, Miller RW, Mitchell C, Napolitano JG, Nere N, Ravn MM, Sheikh A, Wagaw S, Zhang H. Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV. Tetrahedron 2019;75:4271-86. [DOI: 10.1016/j.tet.2019.05.064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 348 |
Leila ARS, Mousa MHA, Frakolaki E, Vassilaki N, Bartenschlager R, Zoidis G, Abdel-Halim M, Abadi AH. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds. ACS Omega 2019;4:11440-54. [PMID: 31460249 DOI: 10.1021/acsomega.9b01242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 349 |
Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 350 |
He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J. Rational design of hepatitis C virus E2 core nanoparticle vaccines.. [DOI: 10.1101/717538] [Reference Citation Analysis]
|
| 351 |
Donyavi T, Bokharaei-Salim F, Khanaliha K, Sheikh M, Bastani MN, Moradi N, Babaei R, Habib Z, Fakhim A, Esghaei M. High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. Arch Virol. 2019;164:2493-2504. [PMID: 31346769 DOI: 10.1007/s00705-019-04353-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 352 |
Paraskevis D, Stylianou DC, Hezka J, Stern Z, Oikonomopoulou M, Mamais I, Kostrikis LG; Cyprus PWID Network. HCV Phylogeography of the General Population and High-Risk Groups in Cyprus Identifies the Island as a Global Sink for and Source of Infection. Sci Rep 2019;9:10077. [PMID: 31296903 DOI: 10.1038/s41598-019-46552-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 353 |
Danesh G, Virlogeux V, Ramière C, Charre C, Cotte L, Alizon S. Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data.. [DOI: 10.1101/689158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 354 |
Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, Han Q, Lv Y, Liu Z. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. Int J Antimicrob Agents 2019;54:780-9. [PMID: 31284039 DOI: 10.1016/j.ijantimicag.2019.07.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 355 |
Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt-yilmaz N, Schiffer CA. Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir.. [DOI: 10.1101/692392] [Reference Citation Analysis]
|
| 356 |
Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells 2019;8:E666. [PMID: 31269695 DOI: 10.3390/cells8070666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 357 |
Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. J Interferon Cytokine Res 2019;39:642-9. [PMID: 31260374 DOI: 10.1089/jir.2019.0013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 358 |
Gulzar W, Niaz Z, Mumtaz SU, Iqtadar S, Komal T, Abaidullah S. Efficacy of Atorvastatin Plus Pegylated Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin Alone in Chronic Hepatitis C Patients with Genotype-3a. PBMJ 2019;2. [DOI: 10.52229/pbmj.v2i1.28] [Reference Citation Analysis]
|
| 359 |
Küçük A, Yıldırım Y. Antiviral İlaçlar. Etlik Veteriner Mikrobiyoloji Dergisi 2019;30:100-108. [DOI: 10.35864/evmd.586573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 360 |
Khedhiri M, Ghedira K, Chouikha A, Touzi H, Sadraoui A, Hammemi W, Triki H. Tracing the epidemic history of hepatitis C virus genotype 1b in Tunisia and in the world, using a Bayesian coalescent approach. Infect Genet Evol 2019;75:103944. [PMID: 31260787 DOI: 10.1016/j.meegid.2019.103944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 361 |
Lioznov DA, Dunaeva NV, Chung NH, Gorchakova OV, Antonova TV. Chronic hepatitis C: modern condition of the problem. Nefrologiâ (St -Peterbg ) 2019;23:36-46. [DOI: 10.24884/1561-6274-2019-23-4-36-46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 362 |
Nii-Trebi NI, Brown CA, Osei YD, Ampofo WK, Nyarko AK. Core encoding sequences of Hepatitis C virus in Ghanaian blood donors are predominantly mosaics of different genotype 2 strains and cannot distinguish subtypes. BMC Infect Dis 2019;19:533. [PMID: 31208352 DOI: 10.1186/s12879-019-4155-4] [Reference Citation Analysis]
|
| 363 |
Hu P, Wilhelm J, Gerresheim GK, Shalamova LA, Niepmann M. Lnc-ITM2C-1 and GPR55 Are Proviral Host Factors for Hepatitis C Virus. Viruses 2019;11:E549. [PMID: 31200545 DOI: 10.3390/v11060549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 364 |
Schwarzkopf R, Novikov D, Anoushiravani AA, Feng JE, Vigdorchik J, Schurko B, Dwyer MK, Bedair HS. The preoperative management of Hepatitis C may improve the outcome after total knee arthroplasty. Bone Joint J 2019;101-B:667-74. [PMID: 31154838 DOI: 10.1302/0301-620X.101B6.BJJ-2018-0723.R3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 365 |
Aboushady M, Alwassief A, Abdelrazik M, Ziada D, Shahba H, Elmestikawy A, Elbahrawy A. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. J Interferon Cytokine Res 2019;39:539-46. [PMID: 31173550 DOI: 10.1089/jir.2019.0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 366 |
O'Brien TR, Jackson SS. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection? J Interferon Cytokine Res 2019;39:618-26. [PMID: 31161939 DOI: 10.1089/jir.2019.0048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 367 |
Gonzalez-miro M, Chen S, Gonzaga ZJ, Evert B, Wibowo D, Rehm BHA. Polyester as Antigen Carrier toward Particulate Vaccines. Biomacromolecules 2019;20:3213-32. [DOI: 10.1021/acs.biomac.9b00509] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 368 |
Miller MM. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes. Am J Health Syst Pharm 2017;74:1045-52. [PMID: 28687550 DOI: 10.2146/ajhp60632] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 369 |
Giannakopoulou E, Pardali V, Frakolaki E, Siozos V, Myrianthopoulos V, Mikros E, Taylor MC, Kelly JM, Vassilaki N, Zoidis G. Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species. Medchemcomm 2019;10:991-1006. [PMID: 31303998 DOI: 10.1039/c9md00200f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 370 |
Chen M, Ma Y, Chen H, Dai J, Luo H, Jia M, Song Z. Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China. PLoS One 2019;14:e0217010. [PMID: 31095618 DOI: 10.1371/journal.pone.0217010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 371 |
Behzadifar M, Heydarvand S, Behzadifar M, Bragazzi NL. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci 2019;29:945-56. [PMID: 30700963 DOI: 10.4314/ejhs.v29i1.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 372 |
Teimoori A, Ebrahimi S, Keshtkar N, Khaghani S, Salmanzadeh S, Ghafari S. Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran. BMC Infect Dis 2019;19:389. [PMID: 31068133 DOI: 10.1186/s12879-019-4052-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 373 |
Quadeer AA, Louie RHY, McKay MR. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Nat Commun 2019;10:2073. [PMID: 31061402 DOI: 10.1038/s41467-019-09819-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 374 |
Iakovenko NO, Zak MY, Klymenko MO, Zhuk SV, Nuzhna OK. METHODS OF TRANSMISSION AND FEATURES OF THE COURSE OF HEPATITIS C VIRUS INFECTION IN CHILDREN: MEDICAL AND SOCIAL ASPECTS. Wiad Lek 2019;72:928-932. [DOI: 10.36740/wlek201905137] [Reference Citation Analysis]
|
| 375 |
Luo A, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore) 2019;98:e15626. [PMID: 31096473 DOI: 10.1097/MD.0000000000015626] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 376 |
Sahuc ME, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, Brodin P, Rosenberg AR, Dubuisson J, Ksouri R, Rouillé Y, Sahpaz S, Séron K. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J Virol 2019;93:e02009-18. [PMID: 30842319 DOI: 10.1128/JVI.02009-18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 377 |
Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 378 |
Ye M, Chen X, Wang Y, Duo L, Zhang C, Zheng YT. Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. Front Microbiol 2019;10:814. [PMID: 31057519 DOI: 10.3389/fmicb.2019.00814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 379 |
Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 380 |
Alkahtani AM, Alsultan MN, Hakami AR, Alamri M. Prevalence of Hepatitis C Virus Genotypes in the Southern Region, Saudi Arabia.. [DOI: 10.1101/603902] [Reference Citation Analysis]
|
| 381 |
Asselah T, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Sci Rep 2019;2:e92. [PMID: 30937389 DOI: 10.1002/hsr2.92] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 382 |
Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019;10:1507. [PMID: 30944315 DOI: 10.1038/s41467-019-09212-y] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 17.3] [Reference Citation Analysis]
|
| 383 |
Lee SS, Kim CY, Kim BR, Cha RR, Kim WS, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea. J Viral Hepat 2019;26:459-65. [PMID: 30516858 DOI: 10.1111/jvh.13047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 384 |
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019;49:1052-9. [PMID: 30874328 DOI: 10.1111/apt.15222] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 385 |
Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC. Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments. Hepatology 2019;69:1426-41. [PMID: 30387174 DOI: 10.1002/hep.30342] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 386 |
Navarro-de la Cruz D, Pérez-castro S, Trigo-daporta M, Aguilera-guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000–2015. Enfermedades infecciosas y microbiologia clinica (English ed ) 2019;37:256-259. [DOI: 10.1016/j.eimce.2018.03.017] [Reference Citation Analysis]
|
| 387 |
Panyala BR, Mukherjee RM, Devarakonda H, Tadivaka S, Padaki NR, Sharma M, Duvvuru NR. Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis. Indian J Gastroenterol 2019;38:110-6. [PMID: 30903612 DOI: 10.1007/s12664-019-00934-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 388 |
Margusino-Framiñán L, Cid-Silva P, Mena-de-Cea A, Rodríguez-Osorio I, Pernas-Souto B, Delgado-Blanco M, Pertega-Díaz S, Martín-Herranz I, Castro-Iglesias A. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Rev Esp Quimioter 2019;32:137-44. [PMID: 30761823] [Reference Citation Analysis]
|
| 389 |
Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 390 |
Minme R, Holzmann I, Tovo CV, Almeida PRL. PROFILE OF PATIENTS WITH CHRONIC HEPATITIS C IN A PUBLIC HEALTH PROGRAM IN SOUTHERN BRAZIL. Arq Gastroenterol 2018;55:403-6. [PMID: 30785526 DOI: 10.1590/S0004-2803.201800000-86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 391 |
Castelo A, Mello CEB, Teixeira R, Madruga JVR, Reuter T, Pereira LMMB, Silva GF, Álvares-DA-Silva MR, Zambrini H, Ferreira PRA. HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE. Arq Gastroenterol 2018;55:329-37. [PMID: 30785514 DOI: 10.1590/S0004-2803.201800000-74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 392 |
Le Ngoc C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, Nguyen Hoa T, Nghiem My N, Le Van T, Le Manh H, Le Thanh P, Nguyen Van Vinh C, Thwaites G, Cooke G, Heilek GM, Shikuma C, Le T, Baker S, Rahman M; VIZIONS consortium. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PLoS One 2019;14:e0212734. [PMID: 30865664 DOI: 10.1371/journal.pone.0212734] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 393 |
Kammarabutr J, Mahalapbutr P, Nutho B, Kungwan N, Rungrotmongkol T. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. J Mol Graph Model 2019;89:122-30. [PMID: 30884449 DOI: 10.1016/j.jmgm.2019.03.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 394 |
Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
|
| 395 |
El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. J Adv Res 2019;17:43-8. [PMID: 31193326 DOI: 10.1016/j.jare.2019.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 396 |
Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 397 |
Wadood M, Usman M. Comparative Analysis of Electrochemiluminescence Assay and Chemiluminescent Microparticle Immunoassay for the Screening of Hepatitis C. Indian J Hematol Blood Transfus 2019;35:131-6. [PMID: 30828160 DOI: 10.1007/s12288-018-0968-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 398 |
Toyoda H. Direct-acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens. Health Sci Rep 2019;2:e106. [PMID: 30937390 DOI: 10.1002/hsr2.106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 399 |
Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 400 |
Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 401 |
Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 402 |
Rasche A, Sander AL, Corman VM, Drexler JF. Evolutionary biology of human hepatitis viruses. J Hepatol 2019;70:501-20. [PMID: 30472320 DOI: 10.1016/j.jhep.2018.11.010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 403 |
Moustafa RI, Dubuisson J, Lavie M. Function of the HCV E1 envelope glycoprotein in viral entry and assembly. Future Virology 2019;14:171-84. [DOI: 10.2217/fvl-2018-0180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 404 |
Barman B, Bora K, Lynrah KG, Lyngdoh WV, Jamil M. Hepatitis C virus and its genotypes in chronic liver disease patients from Meghalaya, Northeast India. Indian J Med Microbiol 2018;36:376-80. [PMID: 30429390 DOI: 10.4103/ijmm.IJMM_17_371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 405 |
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infect Dis 2019;6:ofz076. [PMID: 30949527 DOI: 10.1093/ofid/ofz076] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 406 |
Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 407 |
Botheju WSP, Zghyer F, Mahmud S, Terlikbayeva A, El-Bassel N, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019;9:2090. [PMID: 30765844 DOI: 10.1038/s41598-019-38853-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 408 |
Köksal İ, Yılmaz G, Parlak M, Demirdal T, Kınıklı S, Candan M, Kaya A, Akhan S, Aydoğdu Ö, Turgut H, Gürbüz Y, Dağlı Ö, Gökal AA, Güner R, Kuruüzüm Z, Tarakçı H, Beslen N, Erdoğan S, Özdener F, Study Group TCHC. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study. Turk J Gastroenterol 2018;29:464-72. [PMID: 30249562 DOI: 10.5152/tjg.2018.16597] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 409 |
Shenge JA, Odaibo GN, Olaleye DO. Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria. PLoS One 2019;14:e0210724. [PMID: 30726229 DOI: 10.1371/journal.pone.0210724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 410 |
Yeh TK, Kang IJ, Hsu TA, Lee YC, Lee CC, Hsu SJ, Tian YW, Yang HY, Chen CT, Chao YS, Yueh A, Chern JH. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem 2019;167:245-68. [PMID: 30772607 DOI: 10.1016/j.ejmech.2019.02.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 411 |
Loarec A, Carnimeo V, Molfino L, Kizito W, Muyindike W, Andrieux-Meyer I, Balkan S, Nzomukunda Y, Mwanga-Amumpaire J, Ousley J, Bygrave H, Maman D. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. AIDS 2019;33:353-5. [PMID: 30475267 DOI: 10.1097/QAD.0000000000002070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 412 |
Kilaru SM, Jacobson IM. Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection. Future Virology 2019;14:61-71. [DOI: 10.2217/fvl-2018-0134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 413 |
Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. J Viral Hepat 2019;26:263-70. [PMID: 30380158 DOI: 10.1111/jvh.13032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 414 |
Hua R, Jiang X, Qi L, Guan S, Kuai Z, Qiao Y, Xu Y, Gong X, Shi Y, Kong W, Niu J, Zhang H, Shan Y. Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region. Immunol Res 2018;66:67-73. [PMID: 29151181 DOI: 10.1007/s12026-017-8962-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 415 |
Barnes DM, Shekhar S, Dunn TB, Barkalow JH, Chan VS, Franczyk TS, Haight AR, Hengeveld JE, Kolaczkowski L, Kotecki BJ, Liang G, Marek JC, McLaughlin MA, Montavon DK, Napier JJ. Discovery and Development of Metal-Catalyzed Coupling Reactions in the Synthesis of Dasabuvir, an HCV-Polymerase Inhibitor. J Org Chem 2019;84:4873-92. [PMID: 30629443 DOI: 10.1021/acs.joc.8b02690] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 416 |
Zhu XB, Zhuo LY, Yue M, Liu M, Zang F, Fan HZ, Wu JJ, Xia XS, Zhang AM, Yu RB, Huang P. Genetic variants in IFIH1 and DDX58 influence hepatitis C virus clearance in Chinese Han population. J Med Virol 2019;91:1097-103. [PMID: 30633820 DOI: 10.1002/jmv.25398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 417 |
Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 418 |
Aziz B, Nazar T, Akhlaq S. The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients. Pak J Med Sci 2019;35:101-5. [PMID: 30881405 DOI: 10.12669/pjms.35.1.109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 419 |
Bhattacharjee C, Nandy SK, Das P, Mukhopadhyay A. Differential interaction strategies of hepatitis c virus genotypes during entry - An in silico investigation of envelope glycoprotein E2 - CD81 interaction. Infect Genet Evol 2019;69:48-60. [PMID: 30639544 DOI: 10.1016/j.meegid.2019.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 420 |
Barros MMO, Ronchini KROM, Soares RLS. HEPATITIS B AND C IN PREGNANT WOMEN ATTENDED BY A PRENATAL PROGRAM IN AN UNIVERSITARY HOSPITAL IN RIO DE JANEIRO, BRAZIL: RETROSPECTIVE STUDY OF SEROPREVALENCE SCREENING. Arq Gastroenterol 2018;55:267-73. [PMID: 30540090 DOI: 10.1590/S0004-2803.201800000-68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 421 |
Dash S, Aydin Y, Stephens CM. Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitor. Viral Polymerases 2019. [DOI: 10.1016/b978-0-12-815422-9.00008-5] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 422 |
Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol 2019;34:40-8. [PMID: 30151932 DOI: 10.1111/jgh.14457] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 423 |
Del Rio-Valencia JC, Asensi-Diez R, Tamayo-Bermejo R, Muñoz-Castillo I. Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C. Rev Esp Quimioter 2019;32:296-302. [PMID: 31232572] [Reference Citation Analysis]
|
| 424 |
Chemaitelly H, Mahmud S, Mumtaz GR, Benova L, Ayoub HH, Kouyoumjian SP, Al-kanaani Z, Abu-raddad LJ. Hepatitis C Virus in the Middle East and North Africa. Handbook of Healthcare in the Arab World 2019. [DOI: 10.1007/978-3-319-74365-3_138-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 425 |
Syzova LM, Koval LT, Bodnar VA, Kaydashev IP, Izyumska OМ. PREDICTION OF HEPATIC FIBROSIS PROGRESSION RATE IN CHRONIC HEPATITIS C ON THE BASIS OF CLINICAL AND GENETIC SIGNS. WOMAB 2019;15:151. [DOI: 10.26724/2079-8334-2019-4-70-151-155] [Reference Citation Analysis]
|
| 426 |
Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 427 |
Nguyen E, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther 2019;49:99-106. [PMID: 30467877 DOI: 10.1111/apt.15043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 428 |
Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z, Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 2019;68:140-9. [PMID: 29180585 DOI: 10.1136/gutjnl-2017-314870] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 429 |
Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 26.8] [Reference Citation Analysis]
|
| 430 |
Ozaras R, Leblebicioglu H. Global Epidemiology of Chronic Hepatitis C Virus Infection. Viral Hepatitis: Chronic Hepatitis C 2019. [DOI: 10.1007/978-3-030-03757-4_1] [Reference Citation Analysis]
|
| 431 |
Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 432 |
Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, Mogharbel MH, Mahallawi W, Asselah T, Sanai FM. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol 2019;25:55-60. [PMID: 30117490 DOI: 10.4103/sjg.SJG_189_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 433 |
Aljuboori A, Kaur S, Tahan V. Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients. Viral Hepatitis: Chronic Hepatitis C 2019. [DOI: 10.1007/978-3-030-03757-4_4] [Reference Citation Analysis]
|
| 434 |
Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. Contemporary Oral Medicine 2019. [DOI: 10.1007/978-3-319-72303-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 435 |
Park G, Jo H, Kim H, Kim M, Shin K, Hong S, Chang K. Apolipoprotein E Genotype and Expression Correlated with Hepatitis C Virus Genotype and Infection. J Bacteriol Virol 2019;49:27. [DOI: 10.4167/jbv.2019.49.1.27] [Reference Citation Analysis]
|
| 436 |
Gordon SC, Trudeau S, Li J, Zhou Y, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Lu M; CHeCS investigators. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. J Clin Gastroenterol 2019;53:40-50. [PMID: 28737649 DOI: 10.1097/MCG.0000000000000872] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 437 |
Iwamoto M, Calzia A, Dublineau A, Rouet F, Nouhin J, Yann S, Pin S, Sun C, Sann K, Dimanche C, Lastrucci C, Coulborn RM, Maman D, Dousset JP, Loarec A. Field evaluation of GeneXpert(®) (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia. J Viral Hepat 2019;26:38-47. [PMID: 30199587 DOI: 10.1111/jvh.13002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 438 |
Verhaz A, Kezić Z, Stojiljković M, Škrbić R. Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study. Scripta Medica 2019;50:77-81. [DOI: 10.5937/scriptamed50-22255] [Reference Citation Analysis]
|
| 439 |
Goel A, Ahmed A, Waked I. Clinical Epidemiology of Hepatitis C Virus. Clinical Epidemiology of Chronic Liver Diseases 2019. [DOI: 10.1007/978-3-319-94355-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 440 |
Chen F, Freyer C, Gong L, Zekry A. Hepatitis B Virus, Hepatitis C Virus, the Microbiome, and Hepatocellular Carcinoma. Gastrointestinal Diseases and their Associated Infections 2019. [DOI: 10.1016/b978-0-323-54843-4.00004-0] [Reference Citation Analysis]
|
| 441 |
Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 442 |
O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 443 |
Naderi N, Masoudi G, Behnava B, Alavian SM, Sari S, Anvar A, Azizi Saraji A, Namvar A, Bolhassani A. Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.83337] [Reference Citation Analysis]
|
| 444 |
Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 445 |
Zhu F, Wang Y, Xu Z, Qu H, Zhang H, Niu L, Xue H, Jing D, He H. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice. Mol Med Rep 2019;19:1016-23. [PMID: 30569131 DOI: 10.3892/mmr.2018.9739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 446 |
Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6. [PMID: 30084409 DOI: 10.4103/ijmm.IJMM_17_381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 447 |
Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 448 |
Plaz Torres MC, Lleo A, Aghemo A. Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. Lancet Gastroenterol Hepatol 2019;4:5-6. [PMID: 30527582 DOI: 10.1016/S2468-1253(18)30378-9] [Reference Citation Analysis]
|
| 449 |
Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 450 |
Chen M, Zheng F, Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP. Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. Front Microbiol 2018;9:2950. [PMID: 30564209 DOI: 10.3389/fmicb.2018.02950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 451 |
El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol 2018;12:1265-72. [PMID: 29757684 DOI: 10.1080/17474124.2018.1476137] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 452 |
Almadiyeva A, Ibrayev S, Turgambayeva A, Kostyuk A, Khismetova Z, Akhmetova Z. Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Iran J Public Health 2018;47:1845-53. [PMID: 30788299] [Reference Citation Analysis]
|
| 453 |
Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 454 |
Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 2019;32:108-18. [PMID: 30496620 DOI: 10.1111/sdi.12759] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 455 |
BioMed Central. Correction to: Hepatology, Medicine and Policy: Articles with DOIs 10.1186/s41124-016-0014-8, 10.1186/s41124-016-0013-9 and 10.1186/s41124-016-0012-x. Hepatol Med Policy 2018;3:13. [PMID: 30480669 DOI: 10.1186/s41124-018-0042-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 456 |
Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis viruses in West-African countries from 1996 to 2018. World J Hepatol 2018;10:807-21. [PMID: 30533182 DOI: 10.4254/wjh.v10.i11.807] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 457 |
da Costa Marques Borges LF, Zalis MG, Santoro-Lopes G, Varella RB. Hepatitis C virus genotypes in hemodialysis patients in Angola. J Med Virol 2019;91:518-21. [PMID: 30381830 DOI: 10.1002/jmv.25354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 458 |
Mahmood N, Ali S, Afridi J, Ahmad B, Ali I, Jalil F. Real Time PCR Based Detection of Hepatitis C Virus Major Genotypes in Chronic HCV Patients in Khyber Pakhtunkhwa. Jundishapur J Microbiol 2018;11. [DOI: 10.5812/jjm.80931] [Reference Citation Analysis]
|
| 459 |
Sahuc M, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, Brodin P, Rosenberg AR, Dubuisson J, Ksouri R, Rouillé Y, Sahpaz S, Séron K. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted fromJuncus maritimusIs a New Inhibitor of Hepatitis C Virus Replication.. [DOI: 10.1101/469361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 460 |
Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 461 |
San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 462 |
Rangel JB, Thuler LCS, Pinto JFDC. Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients. Oral Oncol 2018;87:138-43. [PMID: 30527229 DOI: 10.1016/j.oraloncology.2018.10.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 463 |
Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. Infect Drug Resist 2018;11:2117-27. [PMID: 30464554 DOI: 10.2147/IDR.S179158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 464 |
Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45-51. [PMID: 30393106 DOI: 10.1016/s2468-1253(18)30341-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 465 |
Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2018;16:1811-1819.e4. [PMID: 29306043 DOI: 10.1016/j.cgh.2017.12.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 466 |
Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 467 |
Youngberg S, Brandt E, Barve A, Machineni S, Jones CT, Dabovic K, Jones CL, Colvin RA. A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers. J Drug Assess 2018;7:66-74. [PMID: 30370176 DOI: 10.1080/21556660.2018.1535438] [Reference Citation Analysis]
|
| 468 |
Sagnelli E, Alessio L, Sagnelli C, Gualdieri L, Pisaturo M, Minichini C, Di Caprio G, Starace M, Onorato L, Scotto G, Macera M, Coppola N. Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. Ann Hepatol 2018;17:47-53. [PMID: 29311411 DOI: 10.5604/01.3001.0010.7534] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 469 |
Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 87] [Article Influence: 17.2] [Reference Citation Analysis]
|
| 470 |
Jakupi X, M. Lunar M, Mlakar J, Matković I, P. Tavakoli N, Zafirova Ivanovska B, Vince A, Poljak M. HCV Infection among Injecting Drug Users in Prishtina, Kosovo. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.80189] [Reference Citation Analysis]
|
| 471 |
Barathan M, Mohamed R, Yong YK, Kannan M, Vadivelu J, Saeidi A, Larsson M, Shankar EM. Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. Cells 2018;7:E165. [PMID: 30322028 DOI: 10.3390/cells7100165] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 472 |
Warkad SD, Nimse SB, Song KS, Kim T. HCV Detection, Discrimination, and Genotyping Technologies. Sensors (Basel) 2018;18:E3423. [PMID: 30322029 DOI: 10.3390/s18103423] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 473 |
Rehman S. Safety, Tolerability, and Associated Side Effects of Direct- Acting Antivirals. Hepatitis C - From Infection to Cure 2018. [DOI: 10.5772/intechopen.76225] [Reference Citation Analysis]
|
| 474 |
Zignego AL, Monti M, Gragnani L. Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. Acta Biomed 2018;89:321-31. [PMID: 30333452 DOI: 10.23750/abm.v89i3.7718] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
|
| 475 |
Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 476 |
Tsai FJ, Cheng CF, Chen CJ, Lin CY, Wu YF, Li TM, Chuang PH, Wu YC, Lai CH, Liu X, Tsang H, Lin TH, Liao CC, Huang SM, Li JP, Lin JC, Lin CC, Liang WM, Lin YJ. Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. Phytomedicine 2019;57:30-8. [PMID: 30668320 DOI: 10.1016/j.phymed.2018.09.237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 477 |
Jacobson IM. Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis? Gastroenterology 2018;155:969-71. [PMID: 30201359 DOI: 10.1053/j.gastro.2018.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 478 |
Wei L, Omata M, Lim Y, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han K, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research 2018;158:178-84. [DOI: 10.1016/j.antiviral.2018.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 479 |
Gayam V, Tiongson B, Khalid M, Mandal AK, Mukhtar O, Gill A, Garlapati P, Shrestha B, Khalid M, Chakraborty S, Guss D, Sherigar J, Mansour M, Mohanty S. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol 2018;30:1200-7. [PMID: 30096090 DOI: 10.1097/MEG.0000000000001233] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 480 |
Yin P, Hong Z, Zhang L, Ke Y. Retromer localizes to autophagosomes during HCV replication. Virol Sin 2017;32:245-8. [PMID: 28429274 DOI: 10.1007/s12250-016-3914-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 481 |
Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrión JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. Gastroenterology 2018;155:1120-1127.e4. [PMID: 29958855 DOI: 10.1053/j.gastro.2018.06.042] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 482 |
Dağlı Ö, Kasapoğlu aksoy M. Hepatitis B and hepatitis C infection prevalence in ankylosing spondylitis patients. Ortadogu Tıp Derg 2018;10:297-301. [DOI: 10.21601/ortadogutipdergisi.390938] [Reference Citation Analysis]
|
| 483 |
Buivydiene A, Liakina V, Kashuba E, Norkuniene J, Jokubauskiene S, Gineikiene E, Valantinas J. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Medicina (Kaunas) 2018;54:E67. [PMID: 30344298 DOI: 10.3390/medicina54050067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 484 |
Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology (Carlton) 2018;23:446-52. [PMID: 28339162 DOI: 10.1111/nep.13050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 485 |
Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M. Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. J Virol 2018;92:e00939-18. [PMID: 30068644 DOI: 10.1128/JVI.00939-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 486 |
Batista MN, Sanches PRDS, Carneiro BM, Braga ACS, Campos GRF, Cilli EM, Rahal P. GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals. Sci Rep 2018;8:14329. [PMID: 30254334 DOI: 10.1038/s41598-018-32176-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 487 |
Khairy RM, Abdulghany HM, Abdel-Raheim S, Zenhom NM, Abd Elfatah AS, Abdalla NH. Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients. IUBMB Life 2018;70:1156-63. [PMID: 30253037 DOI: 10.1002/iub.1929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 488 |
Tsai SM, Kao JT, Tsai YF. Illness trajectory of initial infection for patients with hepatitis C: A qualitative study. Nurs Health Sci 2019;21:112-8. [PMID: 30251452 DOI: 10.1111/nhs.12568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 489 |
Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 48] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 490 |
Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. J Diabetes Investig 2019;10:418-28. [PMID: 30099847 DOI: 10.1111/jdi.12910] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 491 |
Ali NK, Mohamed RR, Saleh BE, Alkady MM, Farag ES. Occult hepatitis C virus infection among haemodialysis patients. Arab J Gastroenterol. 2018;19:101-105. [PMID: 30245116 DOI: 10.1016/j.ajg.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 492 |
Naseem S, Manzoor S, Javed A, Abbas S. Interleukin-6 Rescues Lymphocyte from Apoptosis and Exhaustion Induced by Chronic Hepatitis C Virus Infection. Viral Immunol 2018;31:624-31. [PMID: 30222516 DOI: 10.1089/vim.2018.0045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 493 |
Adland E, Jesuthasan G, Downs L, Wharton V, Wilde G, McNaughton AL, Collier J, Barnes E, Klenerman P, Andersson M, Jeffery K, Matthews PC. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infect Dis 2018;18:461. [PMID: 30217169 DOI: 10.1186/s12879-018-3367-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 494 |
Owusu M, Bonney JK, Annan AA, Mawuli G, Okyere K, Mutocheluh M, Aryeequaye J, Adjei NK, Afihene M, Spangenberg K, Sylverken J, Owusu-Dabo E, Drosten C, Adu-Sarkodie Y. Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana. PLoS One 2018;13:e0203699. [PMID: 30208084 DOI: 10.1371/journal.pone.0203699] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 495 |
Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci 2018;34:684-8. [PMID: 30527202 DOI: 10.1016/j.kjms.2018.08.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 496 |
Wahid B, Waqar M, Rasool N, Rehman Z, Saeed J, Wasim M, Khan MA, Ali A, Rafique S, Sajjad, Idrees M. Recent trends in molecular epidemiology of Hepatitis C virus in Mardan, KPK Pakistan. Infect Genet Evol 2018;66:66-71. [PMID: 30201500 DOI: 10.1016/j.meegid.2018.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 497 |
Naz A, Mukry SN, Naseer I, Shamsi TS. Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. Pak J Med Sci 2018;34:1204-8. [PMID: 30344577 DOI: 10.12669/pjms.345.15707] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 498 |
Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 499 |
Prakash S, Shukla S, Ramakrishna V, Jain A. Distribution of hepatitis C genotypes in Uttar Pradesh, India; rare genotype 4 detected. J Med Virol 2018;90:1875-81. [PMID: 30085356 DOI: 10.1002/jmv.25277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 500 |
Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int 2018;38:1583-91. [PMID: 29461687 DOI: 10.1111/liv.13727] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 501 |
Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. J Viral Hepat 2018;25:1078-88. [PMID: 29624809 DOI: 10.1111/jvh.12906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 502 |
Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 503 |
Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 504 |
Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure 2018;26:1360-1372.e5. [PMID: 30146168 DOI: 10.1016/j.str.2018.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 505 |
Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 506 |
Bien J, Davulcu A, Delmonte AJ, Fraunhoffer KJ, Gao Z, Hang C, Hsiao Y, Hu W, Katipally K, Littke A, Pedro A, Qiu Y, Sandoval M, Schild R, Soltani M, Tedesco A, Vanyo D, Vemishetti P, Waltermire RE. The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor. Org Process Res Dev 2018;22:1393-408. [DOI: 10.1021/acs.oprd.8b00214] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 507 |
Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 508 |
Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019;105:219-28. [PMID: 29696643 DOI: 10.1002/cpt.1099] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 509 |
Chin-Yee B, Subramanian SV, Verma AA, Laupacis A, Razak F. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy. Milbank Q 2018;96:369-401. [PMID: 29870114 DOI: 10.1111/1468-0009.12328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 510 |
Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 511 |
Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:901-10. [PMID: 30058394 DOI: 10.1080/17425255.2018.1506765] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 512 |
Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. Hepatol Res 2018;48:746-56. [PMID: 29480939 DOI: 10.1111/hepr.13070] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 513 |
Guimarães VDS, Melo TGD, Ferreira RDCD, Almeida SFD, Martins LC. Prevalence of hepatitis C virus genotypes in the State of Pará, Brazil. Rev Soc Bras Med Trop 2018;51:508-12. [DOI: 10.1590/0037-8682-0457-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 514 |
Hoshino K, Sugiyama M, Date T, Maruwaka S, Arakaki S, Shibata D, Maeshiro T, Hokama A, Sakugawa H, Kanto T, Fujita J, Mizokami M. Phylogenetic and phylodynamic analyses of hepatitis C virus subtype 1a in Okinawa, Japan. J Viral Hepat 2018;25:976-85. [PMID: 29577516 DOI: 10.1111/jvh.12898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 515 |
Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-Tack K, Murray J, Birnkrant D, Struble K. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens. J Viral Hepat 2018;25:969-75. [PMID: 29577495 DOI: 10.1111/jvh.12896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 516 |
Iveren WN. Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in Scotland. J Public Health Epidemiol 2018;10:241-250. [DOI: 10.5897/jphe2018.1031] [Reference Citation Analysis]
|
| 517 |
Isakov V, Gankina N, Morozov V, Kersey K, Lu S, Osinusi A, Svarovskaia E, Brainard DM, Salupere R, Orlova-Morozova E, Zhdanov K. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection. Clin Drug Investig 2018;38:239-47. [PMID: 29177645 DOI: 10.1007/s40261-017-0606-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 518 |
Benkheil M, Paeshuyse J, Neyts J, Van Haele M, Roskams T, Liekens S. HCV-induced EGFR-ERK signaling promotes a pro-inflammatory and pro-angiogenic signature contributing to liver cancer pathogenesis. Biochem Pharmacol. 2018;155:305-315. [PMID: 30012461 DOI: 10.1016/j.bcp.2018.07.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 519 |
Kivimets K, Uusküla A, Lazarus JV, Ott K. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infect Dis 2018;18:339. [PMID: 30031373 DOI: 10.1186/s12879-018-3242-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 520 |
Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology 2018;522:177-92. [PMID: 30032031 DOI: 10.1016/j.virol.2018.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 521 |
Ayoub HH, Chemaitelly H, Omori R, Abu-Raddad LJ. Hepatitis C virus infection spontaneous clearance: Has it been underestimated? Int J Infect Dis 2018;75:60-6. [PMID: 30031139 DOI: 10.1016/j.ijid.2018.07.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 522 |
Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, Shiha G, Soliman R, Qaqish RB, Hall C, Alami NN, Kopecky-Bromberg S, Mobashery N. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study. J Med Virol 2018;90:1739-44. [PMID: 29900553 DOI: 10.1002/jmv.25243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 523 |
Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, Ueno T, Hughes E, Bertz R, Garimella T, AbuTarif M. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clin Pharmacokinet 2017;56:1173-83. [PMID: 28066880 DOI: 10.1007/s40262-016-0504-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 524 |
Dikopoulos N, Backhus J, Dollinger M. [The news in hepatitis C therapy]. MMW Fortschr Med 2017;159:43-52. [PMID: 29086258 DOI: 10.1007/s15006-017-9595-4] [Reference Citation Analysis]
|
| 525 |
Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 526 |
Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 527 |
Lu NT, Liu NM, Patel D, Vu JQ, Liu L, Kim CY, Cho P, Khachatoorian R, Patel N, Magyar CE, Ganapathy E, Arumugaswami V, Dasgupta A, French SW. Oncoprotein Stathmin Modulates Sensitivity to Apoptosis in Hepatocellular Carcinoma Cells During Hepatitis C Viral Replication. J Cell Death 2018;11:1179066018785141. [PMID: 30034249 DOI: 10.1177/1179066018785141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 528 |
Chamorro-de-vega E, Gimenez-manzorro A, Sanjurjo M. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Medicina Clínica (English Edition) 2018;151:85-86. [DOI: 10.1016/j.medcle.2017.10.051] [Reference Citation Analysis]
|
| 529 |
Wahid B, Waqar M, Saleem K, Shafi F, Rehman Z, Hanif I, Ahmad HM, Wasim M, Sajjad, Wahid K, Idrees M. Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert ® technology. Future Virology 2018;13:467-74. [DOI: 10.2217/fvl-2017-0158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 530 |
Luxenburger H, Graß F, Baermann J, Boettler T, Marget M, Emmerich F, Panning M, Thimme R, Nitschke K, Neumann-Haefelin C. Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4. J Viral Hepat 2018;25:779-90. [PMID: 29397015 DOI: 10.1111/jvh.12874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 531 |
Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. Adv Ther 2018;35:1087-102. [PMID: 29949038 DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 532 |
Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, Mchutchison JG, Mo H, Svarovskaia E, Shafran SD. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. The Journal of Infectious Diseases 2018;218:1722-9. [DOI: 10.1093/infdis/jiy401] [Cited by in Crossref: 143] [Cited by in F6Publishing: 147] [Article Influence: 28.6] [Reference Citation Analysis]
|
| 533 |
Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018;13:e0199760. [PMID: 29953518 DOI: 10.1371/journal.pone.0199760] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 534 |
Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol 2018; 24(24): 2555-2566 [PMID: 29962813 DOI: 10.3748/wjg.v24.i24.2555] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 535 |
Cowton VM, Singer JB, Gifford RJ, Patel AH. Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. Front Immunol 2018;9:1470. [PMID: 30013555 DOI: 10.3389/fimmu.2018.01470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 536 |
Navarro-de la Cruz D, Pérez-Castro S, Trigo-Daporta M, Aguilera-Guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:256-9. [PMID: 29759421 DOI: 10.1016/j.eimc.2018.03.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 537 |
Soh BYM, Kumar R, Ekstrom VSM, Lin CYH, Thangaraju S, Tan HH, Chan KP, Choong LHL, Teo D, Chow WC. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Med J 2019;60:34-9. [PMID: 29926111 DOI: 10.11622/smedj.2018078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 538 |
Bondy L, Silverman MS. Hepatitis. Evidence-Based Infectious Diseases 2018. [DOI: 10.1002/9781119260363.ch13] [Reference Citation Analysis]
|
| 539 |
Tzarum N, Wilson IA, Law M. The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. Front Immunol 2018;9:1315. [PMID: 29951061 DOI: 10.3389/fimmu.2018.01315] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 540 |
Coyle JR, Goerge E, Kacynski K, Rodgers R, Raines P, Vail LS, Lowhim S. Hepatitis C Virus Infections Associated with Unsafe Injection Practices at a Pain Management Clinic, Michigan, 2014-2015. Pain Med 2017;18:322-9. [PMID: 28204717 DOI: 10.1093/pm/pnw157] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 541 |
Momose H, Matsuoka S, Murayama A, Yamada N, Okuma K, Ikebe E, Hoshi Y, Muramatsu M, Wakita T, Toyota K, Kato T, Hamaguchi I. Evaluation of in vitro screening and diagnostic kits for hepatitis C virus infection. J Clin Virol 2018;105:97-102. [PMID: 29940422 DOI: 10.1016/j.jcv.2018.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 542 |
Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clin Infect Dis 2017;65:13-9. [PMID: 28535298 DOI: 10.1093/cid/cix289] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 543 |
Xie Z, Li Y, Long L, Liang H, Cai W, Shen T. Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. BMC Infect Dis 2018;18:254. [PMID: 29866105 DOI: 10.1186/s12879-018-3153-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 544 |
Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 545 |
Pedersen MS, Fahnøe U, Hansen TA, Pedersen AG, Jenssen H, Bukh J, Schønning K. A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus. J Clin Virol 2018;105:49-56. [PMID: 29886373 DOI: 10.1016/j.jcv.2018.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 546 |
Venables BL, Sin N, Wang AX, Sun LQ, Tu Y, Hernandez D, Sheaffer A, Lee M, Dunaj C, Zhai G, Barry D, Friborg J, Yu F, Knipe J, Sandquist J, Falk P, Parker D, Good AC, Rajamani R, McPhee F, Meanwell NA, Scola PM. P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor. Bioorg Med Chem Lett 2018;28:1853-9. [PMID: 29650290 DOI: 10.1016/j.bmcl.2018.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 547 |
Del Rio-Valencia JC, Asensi-Diez R, Villalobos-Torres L, Muñoz Castillo I. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital. Rev Esp Quimioter 2018;31:226-36. [PMID: 29771105] [Reference Citation Analysis]
|
| 548 |
Guo X, Zhong JY, Li JW. Hepatitis C Virus Infection and Vaccine Development. J Clin Exp Hepatol 2018;8:195-204. [PMID: 29892184 DOI: 10.1016/j.jceh.2018.02.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 549 |
Jamil Z, Waheed Y, Malik M, Durrani AA. Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study. PeerJ 2018;6:e4853. [PMID: 29844992 DOI: 10.7717/peerj.4853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 550 |
Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 551 |
Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control 2017;24:1073274817729240. [PMID: 28975833 DOI: 10.1177/1073274817729240] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 552 |
Lin HM, Wu PS, Hu HS, Chang WC, Wu RH, Tian JN, Chern JH, Yueh A. Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication. J Virol Methods 2018;259:10-7. [PMID: 29782889 DOI: 10.1016/j.jviromet.2018.05.010] [Reference Citation Analysis]
|
| 553 |
de Souza SL, Vidal LL, Ramos J, Cardoso CC, Coelho HSM, Villela-Nogueira CA, Perez RM, Soares MA, Santos AF. Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms. Biomed Res Int 2018;2018:2931486. [PMID: 29888255 DOI: 10.1155/2018/2931486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 554 |
Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T. Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment. Intern Med 2018;57:2843-5. [PMID: 29780129 DOI: 10.2169/internalmedicine.0621-17] [Reference Citation Analysis]
|
| 555 |
Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ. Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese. Drug Des Devel Ther 2018;12:1045-51. [PMID: 29750017 DOI: 10.2147/DDDT.S148117] [Reference Citation Analysis]
|
| 556 |
Sanai FM, Altraif IH, Alswat K, AlZanbagi A, Babatin MA, AlMousa A, Almutairi NH, Aljawad MS, Alghamdi AS, Aljumah AA, Alalwan AM, Al-Hamoudi WK, Assiri AM, Dahlan Y, Alsahafi A, Alothmani HS, AlSaleemi MS, Mousa WA, Albenmousa A, Awny A, Albiladi H, Abdo AA, AlGhamdi H. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. J Infect 2018;76:536-42. [PMID: 29742470 DOI: 10.1016/j.jinf.2018.04.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 557 |
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol 2018;68:895-903. [PMID: 29221887 DOI: 10.1016/j.jhep.2017.11.032] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 14.4] [Reference Citation Analysis]
|
| 558 |
Cheung TT, Yan Chiu JW, Yuen MF, Ling Lam KS, Yung Cheung BM, Feng HP, Yeh WW, Wang J, Li W, Zhao XM, Wang Z, Mu S. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. Clin Ther 2018;40:719-732.e1. [PMID: 29724498 DOI: 10.1016/j.clinthera.2018.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 559 |
Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 2018;68:904-11. [PMID: 29233630 DOI: 10.1016/j.jhep.2017.12.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 560 |
Forni D, Cagliani R, Pontremoli C, Pozzoli U, Vertemara J, De Gioia L, Clerici M, Sironi M. Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Front Microbiol 2018;9:854. [PMID: 29765366 DOI: 10.3389/fmicb.2018.00854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 561 |
Liu X, Gao Y, Niu J. Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.66007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 562 |
Brandão R, Marcelino R, Gonçalves F, Diogo I, Carvalho A, Cabanas J, Costa I, Brogueira P, Ventura F, Miranda A, Mansinho K, Gomes P. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018;10:E223. [PMID: 29701642 DOI: 10.3390/v10050223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 563 |
Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res 2017;37:348-53. [PMID: 28777714 DOI: 10.1089/jir.2016.0131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 564 |
Tarragô AM, Pereira GL, Victória FDS, Marie AMA, Victória MB. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon. Rev Soc Bras Med Trop 2017;50:861-3. [PMID: 29340469 DOI: 10.1590/0037-8682-0094-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 565 |
Mahassadi AK, Nguieguia JLK, Kissi HY, Awuah AA, Bangoura AD, Doffou SA, Attia AK. Systemic inflammatory response syndrome and model for end-stage liver disease score accurately predict the in-hospital mortality of black African patients with decompensated cirrhosis at initial hospitalization: a retrospective cohort study. Clin Exp Gastroenterol 2018;11:143-52. [PMID: 29670387 DOI: 10.2147/CEG.S140655] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 566 |
Iakovenko NO, Petro Mohyla Black Sea National University 10, 68 Desantnykiv St., Mikolayiv 54003, Ukraine, Zak MY, Zhuk SV, Nuzhna OK. Features of the Course of Viral Hepatitis C in Children. Ukr ž med bìol sportu 2018;4:51-58. [DOI: 10.26693/jmbs04.02.051] [Reference Citation Analysis]
|
| 567 |
Bassig BA, Willhauck-fleckenstein M, Shu X, Koh W, Gao Y, Purdue MP, Xiang Y, Adams-haduch J, Wang R, Brenner N, Waterboer T, Michel A, Ji B, Hosgood HD, Rabkin CS, Yang G, Wong JY, Zhang J, Hu W, Seow WJ, Chow W, Pawlita M, Zheng W, Yuan J, Lan Q, Rothman N. Serologic markers of viral infection and risk of non-Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore: Serologic markers of viral infection and risk of non-Hodgkin lymphoma. Int J Cancer 2018;143:570-9. [DOI: 10.1002/ijc.31385] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 568 |
Zhang H, Zhu X, Li Q, Lou J, Sun J, Shen Z, Chen H, Li X, Wu M, Li C, Liu J, Liu C, Hu Y, Wang J, Chen G, Ding Y, Niu J. Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus. J Pharm Pharmacol 2018;70:855-64. [PMID: 29630721 DOI: 10.1111/jphp.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 569 |
Hopcraft SE, Damania B. Tumour viruses and innate immunity. Philos Trans R Soc Lond B Biol Sci 2017;372:20160267. [PMID: 28893934 DOI: 10.1098/rstb.2016.0267] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 570 |
Sohail A, Khan S, Ullah R, Qureshi SA, Bilal M, Khan A. Analysis of hepatitis C infection using Raman spectroscopy and proximity based classification in the transformed domain. Biomed Opt Express 2018;9:2041-55. [PMID: 29760968 DOI: 10.1364/BOE.9.002041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 571 |
Gutiérrez-Aroca JB, Ruiz-Martínez P, Rodríguez-Ruiz L, Casal-Román M. Distribution of the genotype of the Hepatitis C Virus in Cordoba-Spain. Rev Esp Quimioter 2018;31:164-5. [PMID: 29616511] [Reference Citation Analysis]
|
| 572 |
Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M, Bayle O, Beaurain P, Monnet O, Bourlière M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol 2018;30:368-75. [PMID: 29384796 DOI: 10.1097/MEG.0000000000001082] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 573 |
Li W, Xi L, Cai Q, Kang Y, Zeng Q, Ding R, Sun C, Shang J. Changes in the distribution of hepatitis C virus genotypes and their association with shifts in transmission routes in Henan, China. J Public Health 2018;26:157-162. [DOI: 10.1007/s10389-017-0845-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 574 |
Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol 2018;68:814-26. [PMID: 29229584 DOI: 10.1016/j.jhep.2017.11.037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 575 |
Li C, Hu J. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Medicine (Baltimore) 2018;97:e0416. [PMID: 29642211 DOI: 10.1097/MD.0000000000010416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 576 |
Shimizu Y, Shirasago Y, Kondoh M, Suzuki T, Wakita T, Hanada K, Yagi K, Fukasawa M. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. J Virol 2018;92:e02258-17. [PMID: 29437969 DOI: 10.1128/JVI.02258-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 577 |
Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities. South Afr J HIV Med 2018;19:737. [PMID: 29707384 DOI: 10.4102/sajhivmed.v19i1.737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 578 |
Corcorran MA, Scott JD. Treatment of DAA-Experienced Patients with Chronic Hepatitis C. Curr Hepatology Rep 2018;17:121-9. [DOI: 10.1007/s11901-018-0395-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 579 |
Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol 2018; 24(11): 1269-1277 [PMID: 29568207 DOI: 10.3748/wjg.v24.i11.1269] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 580 |
Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 581 |
Çakmak E. The Real-World Efficacy and Safety of Direct-Acting Oral Antiviral Treatment in Chronic Hepatitis C Genotype 1 Patients in Turkey. Cumhuriyet Medical Journal 2018. [DOI: 10.7197/223.vi.376221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 582 |
Li CW, Yang CJ, Sun HY, Tsai MS, Lin SP, Lin TY, Cheng CY, Lee YC, Huang YS, Liu CE, Lee YT, Tang HJ, Wang NC, Cheng SH, Ko WC, Hung CC; Taiwan HIV Study Group. Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One 2018;13:e0194149. [PMID: 29547628 DOI: 10.1371/journal.pone.0194149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 583 |
Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-237. [PMID: 29116550 DOI: 10.1007/s11904-017-0369-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 584 |
Carrion AF, Martin P. Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother 2018;19:413-9. [PMID: 29465262 DOI: 10.1080/14656566.2018.1444030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 585 |
Toshikuni N. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver 2017;11:335-48. [PMID: 27840363 DOI: 10.5009/gnl15458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 586 |
Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Gane EJ, Feld JJ, Mangia A. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int 2018;38:443-50. [PMID: 28756625 DOI: 10.1111/liv.13534] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 587 |
Wahid B, Rafique S, Saleem K, Ali A, Idrees M. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. Journal of Interferon & Cytokine Research 2018;38:122-8. [DOI: 10.1089/jir.2017.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 588 |
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol 2018;16:417-26. [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027] [Cited by in Crossref: 168] [Cited by in F6Publishing: 173] [Article Influence: 33.6] [Reference Citation Analysis]
|
| 589 |
Younossi ZM, Chan HLY, Dan YY, Lee MH, Lim YS, Kruger E, Tan SC. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat 2018;25:228-35. [PMID: 29053909 DOI: 10.1111/jvh.12808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 590 |
Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. Eur J Gastroenterol Hepatol 2018;30:302-9. [PMID: 29271782 DOI: 10.1097/MEG.0000000000001035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 591 |
Kantarjian HM, Paul S. Hepatitis C: When high drug prices preclude patient benefit. Cancer 2018;124:1644-6. [PMID: 29486061 DOI: 10.1002/cncr.31292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 592 |
Naghipour-khalkhaliani D, Behzadpour D, Mousavi Nasab SD. Distribution of Hepatitis C Virus Genotypes in Rasht, Capital City of Guilan Province, Northern Part of Iran. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 593 |
Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort. World J Gastroenterol 2018; 24(7): 852-861 [PMID: 29467555 DOI: 10.3748/wjg.v24.i7.852] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 594 |
Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 25.6] [Reference Citation Analysis]
|
| 595 |
Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One 2018;13:e0193112. [PMID: 29466415 DOI: 10.1371/journal.pone.0193112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 596 |
Séron K, Sahuc M, Rouillé Y. Natural Products and Hepatitis C Virus. In: Mérillon J, Riviere C, editors. Natural Antimicrobial Agents. Cham: Springer International Publishing; 2018. pp. 289-327. [DOI: 10.1007/978-3-319-67045-4_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 597 |
Zhu DY, Deng XZ, Zhu YM, Li GT, Zhang GQ, Wang LJ, Zhang JH, Xiao W, Zhou ZX, Ding WL. Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. Arch Virol 2018;163:1253-62. [PMID: 29399747 DOI: 10.1007/s00705-018-3750-9] [Reference Citation Analysis]
|
| 598 |
Weil C, Mehta D, Koren G, Pinsky B, Samp JC, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. J Viral Hepat 2018;25:144-51. [PMID: 28984012 DOI: 10.1111/jvh.12800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 599 |
Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther 2018;47:421-31. [PMID: 29193226 DOI: 10.1111/apt.14428] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 600 |
Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, Cohen DE, Gane E. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). J Viral Hepat 2018;25:118-25. [PMID: 28833938 DOI: 10.1111/jvh.12782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 601 |
Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 2018;67:505-13. [PMID: 28865152 DOI: 10.1002/hep.29510] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 16.4] [Reference Citation Analysis]
|
| 602 |
Saad Y, Awad A, Alakel W, Doss W, Awad T, Mabrouk M. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients. Eur J Gastroenterol Hepatol 2018;30:201-6. [PMID: 29099423 DOI: 10.1097/MEG.0000000000001008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 603 |
Dawson S, Meader E. Hepatitis C. InnovAiT 2018;11:101-108. [DOI: 10.1177/1755738017740161] [Reference Citation Analysis]
|
| 604 |
Del Rio-Valencia JC, Asensi-Diez R, Madera-Pajin R, Yunquera-Romero L, Muñoz-Castillo I. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital. Rev Esp Quimioter 2018;31:35-42. [PMID: 29376623] [Reference Citation Analysis]
|
| 605 |
Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. J Med Virol 2018;90:919-25. [PMID: 29315652 DOI: 10.1002/jmv.25023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 606 |
Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8:1661. [PMID: 29374178 DOI: 10.1038/s41598-017-17936-4] [Cited by in Crossref: 94] [Cited by in F6Publishing: 104] [Article Influence: 18.8] [Reference Citation Analysis]
|
| 607 |
Xiao S, Tian Z, Wang Y, Si L, Zhang L, Zhou D. Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. Med Res Rev 2018;38:951-76. [PMID: 29350407 DOI: 10.1002/med.21484] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 608 |
Manomaivat T, Pongsiriwet S, Kuansuwan C, Thosaporn W, Tachasuttirut K, Iamaroon A. Association between hepatitis C infection in Thai patients with oral lichen planus: A case-control study. J Investig Clin Dent 2018;9:e12316. [PMID: 29345111 DOI: 10.1111/jicd.12316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 609 |
Jancoriene L, Polubenko K, Kazenaite E, Buivydiene A, Jakutiene J, Tolmane I, Jeruma A, Radzisauskiene D, Mockiene E, Ambrozaitis A. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 610 |
Sridhar S, Yip CCY, Chan JFW, To KKW, Cheng VCC, Yuen KY. Impact of inter-genotypic recombination and probe cross-reactivity on the performance of the Abbott RealTime HCV Genotype II assay for hepatitis C genotyping. Diagn Microbiol Infect Dis 2018;91:34-7. [PMID: 29434000 DOI: 10.1016/j.diagmicrobio.2017.12.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 611 |
Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M; GRUviC Study Group. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf 2018;17:235-41. [PMID: 29325476 DOI: 10.1080/14740338.2018.1424829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 612 |
Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018;8:150. [PMID: 29317673 DOI: 10.1038/s41598-017-18296-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 613 |
Ahmadi-Ghezeldasht S, Badiei Z, Sima HR, Hedayati-Moghaddam MR, Habibi M, Khamooshi M, Azimi A. Distribution of Hepatitis C Virus Genotypes in Patients with Major β-Thalassemia in Mashhad, Northeast Iran. Middle East J Dig Dis 2018;10:35-9. [PMID: 29682246 DOI: 10.15171/mejdd.2017.88] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 614 |
von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine 2018;36:313-21. [PMID: 29203182 DOI: 10.1016/j.vaccine.2017.10.079] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 615 |
Ghasemi F, Ghayour-Mobarhan M, Gouklani H, Meshkat Z. Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein. Iran J Pathol 2018;13:113-24. [PMID: 30697280] [Reference Citation Analysis]
|
| 616 |
Collier MG, Holtzman D, Holmberg SD. Hepatitis C Virus. Principles and Practice of Pediatric Infectious Diseases 2018. [DOI: 10.1016/b978-0-323-40181-4.00220-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 617 |
Aziz AA. Hepatitis C Virus. Hepatitis C in Developing Countries 2018. [DOI: 10.1016/b978-0-12-803233-6.00001-1] [Reference Citation Analysis]
|
| 618 |
Froes-meyer P, Musa OM, Eltahir Saeed WS, Ahmed ME, Osman OA, Mohammed HK, Gasim Khalil EA. Biochemical aberrations, viral genotypic patterns and viral loads among Sudanese patients with chronic hepatitis C virus infection. JHVRV 2018;6:51-54. [DOI: 10.15406/jhvrv.2018.06.00195] [Reference Citation Analysis]
|
| 619 |
Jarad Peranteau A, Vangipuram R, Sharghi K, Tyring SK. Systemic Antivirals in Dermatology. Biologic and Systemic Agents in Dermatology 2018. [DOI: 10.1007/978-3-319-66884-0_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 620 |
Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. Contemporary Oral Medicine 2018. [DOI: 10.1007/978-3-319-28100-1_9-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 621 |
Hafez TA. Public Health and Economic Burden of Hepatitis C Infection in Developing Countries. Hepatitis C in Developing Countries 2018. [DOI: 10.1016/b978-0-12-803233-6.00003-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 622 |
Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterología y Hepatología (English Edition) 2018;41:2-11. [DOI: 10.1016/j.gastre.2017.09.002] [Reference Citation Analysis]
|
| 623 |
St. John TM. Chronic Hepatitis. Integrative Medicine 2018. [DOI: 10.1016/b978-0-323-35868-2.00021-9] [Reference Citation Analysis]
|
| 624 |
Ward JW, Holtzman D. Epidemiology, Natural History, and Diagnosis of Hepatitis C. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00029-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 625 |
Chamorro-de-Vega E, Gimenez-Manzorro A, Sanjurjo M; GRUVIC Study Group. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Med Clin (Barc) 2018;151:85-6. [PMID: 29295791 DOI: 10.1016/j.medcli.2017.10.041] [Reference Citation Analysis]
|
| 626 |
Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis 2016;63 Suppl 1:S3-S11. [PMID: 27363438 DOI: 10.1093/cid/ciw219] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 627 |
Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2017;19:E23. [PMID: 29271914 DOI: 10.3390/ijms19010023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 628 |
Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13. [PMID: 29271117 DOI: 10.1111/apm.12790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 629 |
Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 630 |
Hernández-Vásquez A, Rosselli D. A bibliometric analysis of the global research on sofosbuvir. F1000Res 2017;6:1536. [PMID: 29259762 DOI: 10.12688/f1000research.12314.1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 631 |
Mhalla S, Hammoud R, Frih A, Kadri Y, El Argoubi A, Elmay M, Mastouri M. Prevalence and risk factors of hepatitis B and C among hemodialysis patients in Tunisia. Med Mal Infect 2018;48:175-9. [PMID: 29249466 DOI: 10.1016/j.medmal.2017.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 632 |
Trapani S, Rizzato L, Masiero L, Ricci A, Morabito V, Peritore D, Fiaschetti P, Del Sordo E, Cacciotti AR, Montemurro A, Nanni Costa A. Hepatitis C Virus Positive Patients on the Waiting List for Liver Transplantation: Turnover and Characteristics of the Population on the Eve of the Therapeutic Revolution With Direct-Acting Antivirals. Transplant Proc 2017;49:658-66. [PMID: 28457366 DOI: 10.1016/j.transproceed.2017.02.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 633 |
Morgan JR, Kim AY, Naggie S, Linas BP. The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infect Dis 2018;5:ofx267. [PMID: 29354660 DOI: 10.1093/ofid/ofx267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 634 |
Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, Prieto M, Moreno JM, Sánchez-Antolín G, Vergara M, Forné M, Fernández I, Castro MA, Pascual S, Gómez A, Castells L, Montero JL, Crespo J, Calleja JL, García-Samaniego J, Carrión JA, Arencibia AC, Blasco A, López-Núñez C, Sánchez-Ruano JJ, Gea-Rodríguez F, Giráldez Á, Cabezas J, Hontangas V, Torras X, Castellote J, Romero-Gómez M, Turnes J, de Artaza T, Narváez I, Cuervas-Mons V, Forns X. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver Int 2017;37:1823-32. [PMID: 28481460 DOI: 10.1111/liv.13470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 635 |
Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017;96:e9271. [PMID: 29390377 DOI: 10.1097/MD.0000000000009271] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 636 |
Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L. Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. Am J Gastroenterol 2017;112:1824-31. [PMID: 29087397 DOI: 10.1038/ajg.2017.399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 637 |
Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017;9:1239-52. [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 638 |
Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T. Increased hope following successful treatment for hepatitis C infection. J Adv Nurs 2018;74:724-33. [PMID: 29082540 DOI: 10.1111/jan.13487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 639 |
Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology 2018;514:134-41. [PMID: 29175627 DOI: 10.1016/j.virol.2017.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 640 |
Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017;7:16017. [PMID: 29167469 DOI: 10.1038/s41598-017-15987-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 641 |
Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. Proteases and protease inhibitors in infectious diseases. Med Res Rev 2018;38:1295-331. [PMID: 29149530 DOI: 10.1002/med.21475] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 642 |
Goonawardane N, Ross-Thriepland D, Harris M. Regulation of hepatitis C virus replication via threonine phosphorylation of the NS5A protein. J Gen Virol 2018;99:62-72. [PMID: 29139348 DOI: 10.1099/jgv.0.000975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 643 |
Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018;41:2-11. [PMID: 29150360 DOI: 10.1016/j.gastrohep.2017.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 644 |
Zeng N, Zou C, He Z, Ma H, Ou X, You H, Kong Y, Jia J. Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. Int J Infect Dis 2018;67:58-64. [PMID: 29138012 DOI: 10.1016/j.ijid.2017.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 645 |
Adland E, Jesuthasan G, Downs L, Wharton V, Wilde G, Mcnaughton A, Collier J, Barnes E, Klenerman P, Andersson M, Jeffery K, Matthews PC. Hepatitis C Virus (HCV) diagnosis, epidemiology and access to treatment in a UK cohort.. [DOI: 10.1101/216937] [Reference Citation Analysis]
|
| 646 |
Hartlage AS, Cullen JM, Kapoor A. The Strange, Expanding World of Animal Hepaciviruses. Annu Rev Virol 2016;3:53-75. [PMID: 27741408 DOI: 10.1146/annurev-virology-100114-055104] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 647 |
Dussaq AM, Soni A, Willey C, Park SL, Harada S. Hepatitis C Virus Genie: A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus Genotype Line Probe Assay Version 2.0. J Pathol Inform 2017;8:41. [PMID: 29114435 DOI: 10.4103/jpi.jpi_44_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 648 |
Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 2018;90:304-12. [PMID: 28710853 DOI: 10.1002/jmv.24903] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 649 |
Mania A, Kaczmarek M, Kemnitz P, Mazur-Melewska K, Figlerowicz M, Sikora J, Służewski W, Żeromski J. Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C. Med Microbiol Immunol 2018;207:55-63. [PMID: 29119253 DOI: 10.1007/s00430-017-0526-x] [Reference Citation Analysis]
|
| 650 |
Chahine EB, Kelley D, Childs-Kean LM. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother. 2018;52:352-363. [PMID: 29115151 DOI: 10.1177/1060028017741508] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 651 |
Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 652 |
Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shawkat M, Yousif S, Ullah W, Alabbad S, Al-Jedai A, Ajlan A, Broering D, Saab S, Al Sebayel M, Al-Hamoudi W. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation 2017;101:2739-45. [PMID: 28795982 DOI: 10.1097/TP.0000000000001907] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 653 |
Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader AG. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. Virol J 2017;14:208. [PMID: 29096662 DOI: 10.1186/s12985-017-0873-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 654 |
Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat 2017;24:936-43. [PMID: 28480525 DOI: 10.1111/jvh.12722] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 655 |
Johnson KL, Hertz D, Stobbe G, Alschuler K, Kalb R, Alexander KS, Kraft GH, Scott JD. Project Extension for Community Healthcare Outcomes (ECHO) in Multiple Sclerosis: Increasing Clinician Capacity. Int J MS Care 2017;19:283-9. [PMID: 29270085 DOI: 10.7224/1537-2073.2016-099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 656 |
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang H, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su F, Wan S, Zeng Z, Chen H, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. The Lancet Gastroenterology & Hepatology 2017;2:805-13. [DOI: 10.1016/s2468-1253(17)30159-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 657 |
Maddur H, Flamm SL. Hepatitis C Genotype 3 Infection: Pathogenesis and Treatment Horizons. Clin Liver Dis 2017;21:645-57. [PMID: 28987253 DOI: 10.1016/j.cld.2017.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 658 |
Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect 2017;6:e95. [PMID: 29089588 DOI: 10.1038/emi.2017.77] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 659 |
Romero-López C, Berzal-Herranz A. The 5BSL3.2 Functional RNA Domain Connects Distant Regions in the Hepatitis C Virus Genome. Front Microbiol 2017;8:2093. [PMID: 29163393 DOI: 10.3389/fmicb.2017.02093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 660 |
Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 661 |
Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert ML, Joos TO, Schneiderhan-Marra N. Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. High Throughput 2017;6:E15. [PMID: 29855459 DOI: 10.3390/ht6040015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 662 |
Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 663 |
Fried MW, Darling JM, Lemon SM. Hepatitis C. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch25] [Reference Citation Analysis]
|
| 664 |
Hu L, Li J, Cai H, Yao W, Xiao J, Li YP, Qiu X, Xia H, Peng T. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Res 2017;148:5-14. [PMID: 29074218 DOI: 10.1016/j.antiviral.2017.10.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 665 |
Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clin Pharmacokinet 2016;55:1091-101. [PMID: 27000758 DOI: 10.1007/s40262-016-0385-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 666 |
Nguyen LT, Van Nguyen D, Carr MJ, Hall WW, Nguyen LA. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Arch Virol 2018;163:115-24. [PMID: 29022122 DOI: 10.1007/s00705-017-3583-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 667 |
Afsheen Z, Ahmad B, Bashir S. Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. Virol J 2017;14:195. [PMID: 29017555 DOI: 10.1186/s12985-017-0861-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 668 |
Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 18.7] [Reference Citation Analysis]
|
| 669 |
Harfouche M, Chemaitelly H, Mahmud S, Chaabna K, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. Epidemiol Infect. 2017;145:3243-3263. [PMID: 28988562 DOI: 10.1017/s0950268817002242] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 670 |
Fan Z, Zhang Q, Chen H, He P, Li Y, Si M, Jiao X. Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. Microb Pathog 2017;112:320-6. [PMID: 28993299 DOI: 10.1016/j.micpath.2017.10.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 671 |
Awady MKE, Dawood RM. Resistance to Direct-Acting Antiviral Agents in Treatment of Hepatitis C Virus Infections. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70729] [Reference Citation Analysis]
|
| 672 |
Smolić M, Omanović T, Božić I, Bilić-ćurčić I, Smolić R, Včev A. Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70794] [Reference Citation Analysis]
|
| 673 |
Lee AS, van Driel ML, Crawford DH. The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. Clinicoecon Outcomes Res 2017;9:595-607. [PMID: 29042803 DOI: 10.2147/CEOR.S146280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 674 |
Kerkerian G, Alimohammadi A, Raycraft T, Conway B. Repeated spontaneous clearance of hepatitis C virus infection in the setting of long-term non-progression of HIV infection. Infect Dis Rep 2017;9:7142. [PMID: 29071045 DOI: 10.4081/idr.2017.7142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 675 |
He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther 2017;46:711-21. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 676 |
Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat 2017;24:895-9. [PMID: 28470815 DOI: 10.1111/jvh.12719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 677 |
Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 678 |
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52. [PMID: 27418632 DOI: 10.1136/gutjnl-2016-311609] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 679 |
Kelly L, Badhan A, Roberts GC, Mbisa JL, Harris M. Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon. J Gen Virol 2017;98:2495-506. [PMID: 28984238 DOI: 10.1099/jgv.0.000932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 680 |
Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 681 |
Kang MG, Kang MJ, Ji E, Yoo BK. Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection. Korean J Clin Pharm 2017;27:150-160. [DOI: 10.24304/kjcp.2017.27.3.150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 682 |
Kalinina OV, Lichnaia EV, Boiro MY, Totolian AA. THE OCCURRENCE OF THE MARKERS OF HEPATITIS C AMONG PRACTICALLY HEALTHY RESIDENTS OF THE REPUBLIC OF GUINEA: A PILOT STUDY. Russian Journal of Infection and Immunity 2017;7:245-250. [DOI: 10.15789/2220-7619-2017-3-245-250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 683 |
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. J Med Virol. 2018;90:109-119. [PMID: 28842997 DOI: 10.1002/jmv.24923] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 684 |
Fakhriravari A. Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C - A Review. GHOA 2017;7. [DOI: 10.15406/ghoa.2017.07.00254] [Reference Citation Analysis]
|
| 685 |
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 686 |
Behrendt P, Perin P, Menzel N, Banda D, Pfaender S, Alves MP, Thiel V, Meuleman P, Colpitts CC, Schang LM, Vondran FWR, Anggakusuma, Manns MP, Steinmann E, Pietschmann T. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Res 2017;147:19-28. [PMID: 28923507 DOI: 10.1016/j.antiviral.2017.09.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 687 |
Bessa LM, Launay H, Dujardin M, Cantrelle FX, Lippens G, Landrieu I, Schneider R, Hanoulle X. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B. J Biol Chem 2017;292:18024-43. [PMID: 28912275 DOI: 10.1074/jbc.M117.813766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 688 |
Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2018;90:131-141. [PMID: 28842995 DOI: 10.1002/jmv.24921] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 689 |
Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver Int 2017;37:1304-13. [PMID: 28135777 DOI: 10.1111/liv.13376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 690 |
Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 691 |
Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H, D'Alteroche L, Leroy V, Bourliere M, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Fedchuk L, Akremi R, Bennai Y, Filipovics A, Zhao Y, Bronowicki JP. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int 2017;37:1314-24. [PMID: 28177199 DOI: 10.1111/liv.13383] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 692 |
Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci 2017;62:387-92. [PMID: 28554119 DOI: 10.1016/j.advms.2017.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 693 |
Mishchenko EL, Petrovskaya OV, Mishchenko AM, Petrovskiy ED, Ivanisenko NV, Ivanisenko VA. Integrated mathematical models for describing complex biological processes. BIOPHYSICS 2017;62:778-795. [DOI: 10.1134/s0006350917050141] [Reference Citation Analysis]
|
| 694 |
Manee N, Thongbaiphet N, Pasomsub E, Chantratita W. Clinical evaluation of a newly developed automated massively parallel sequencing assay for hepatitis C virus genotyping and detection of resistance-association variants. Comparison with a line probe assay. J Virol Methods 2017;249:31-7. [PMID: 28851606 DOI: 10.1016/j.jviromet.2017.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 695 |
Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6] [Cited by in Crossref: 248] [Cited by in F6Publishing: 255] [Article Influence: 41.3] [Reference Citation Analysis]
|
| 696 |
Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 697 |
Lin C, Dutta S, Ding B, Wang T, Zadeikis N, Asatryan A, Kort J, Campbell A, Podsadecki T, Liu W. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. The Journal of Clinical Pharmacology 2017;57:1616-24. [DOI: 10.1002/jcph.959] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 698 |
Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017;2:814-823. [PMID: 28802814 DOI: 10.1016/s2468-1253(17)30163-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 699 |
Plissonnier ML, Lahlali T, Raab M, Michelet M, Romero-López C, Rivoire M, Strebhardt K, Durantel D, Levrero M, Mehlen P, Zoulim F, Parent R. Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. Oncogene 2017;36:6712-24. [PMID: 28783179 DOI: 10.1038/onc.2017.271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 700 |
Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017;9:E212. [PMID: 28783119 DOI: 10.3390/v9080212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 701 |
Sadeghi S, Davari M, Asli E, Gharibzadeh S, Vaziri F, Jamnani FR, Fateh A, Siadat SD. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin. Gene 2017;630:28-34. [PMID: 28827115 DOI: 10.1016/j.gene.2017.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 702 |
Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C. Pak J Med Sci 2017;33:813-7. [PMID: 29067045 DOI: 10.12669/pjms.334.12785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 703 |
Wu Q, Li Z, Liu Q. Treatment with PTEN-Long protein inhibits hepatitis C virus replication. Virology 2017;511:1-8. [PMID: 28783500 DOI: 10.1016/j.virol.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 704 |
Zhang S, Sun F, Ren T, Duan Y, Gu H, Lai C, Wang Z, Zhang P, Wang X, Yang P. Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice. Antiviral Res 2017;145:168-74. [PMID: 28778831 DOI: 10.1016/j.antiviral.2017.07.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 705 |
Younossi ZM. Hepatitis C Infection: A Systemic Disease. Clin Liver Dis 2017;21:449-53. [PMID: 28689584 DOI: 10.1016/j.cld.2017.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 706 |
Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis 2017;21:579-94. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 707 |
Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66:389-97. [PMID: 28128852 DOI: 10.1002/hep.29081] [Cited by in Crossref: 154] [Cited by in F6Publishing: 152] [Article Influence: 25.7] [Reference Citation Analysis]
|
| 708 |
Welzel TM, Bhardwaj N, Hedskog C, Chodavarapu K, Camus G, McNally J, Brainard D, Miller MD, Mo H, Svarovskaia E, Jacobson I, Zeuzem S, Agarwal K. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol 2017;67:224-36. [PMID: 28343981 DOI: 10.1016/j.jhep.2017.03.014] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 709 |
Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017;67:263-71. [PMID: 28412293 DOI: 10.1016/j.jhep.2017.03.039] [Cited by in Crossref: 236] [Cited by in F6Publishing: 240] [Article Influence: 39.3] [Reference Citation Analysis]
|
| 710 |
Lu J, Xiang X, Cao Z, Wang W, Zhao G, Tang W, Chen L, Guo S, Zhuang Y, Shi D, Chen L, Bao S, Cai W, Wang H, Zhou H, Xie Q. Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. J Med Virol. 2017;89:1973-1980. [PMID: 28671305 DOI: 10.1002/jmv.24894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 711 |
Valkov I, Ivanova R, Alexiev A, Antonov K, Mateva L. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C. J Clin Diagn Res 2017;11:OC15-20. [PMID: 28969178 DOI: 10.7860/JCDR/2017/28609.10459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 712 |
Tauste R, Moreno-navarro F, Gallego R, Rubio-gámez MC. Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. Mater construcc 2017;7:131. [DOI: 10.3989/mc.2017.04916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 713 |
Esmat S, Garem NE, Raslan H, Elfekki M, Sleem GA. Critical flicker frequency is diagnostic of minimal hepatic encephalopathy. J Investig Med 2017;65:1131-5. [PMID: 28743700 DOI: 10.1136/jim-2017-000428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 714 |
Mattar EH, Almehdar HA, Uversky VN, Redwan EM. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4. Mol Biosyst 2016;12:2785-97. [PMID: 27327492 DOI: 10.1039/c6mb00283h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 715 |
Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T. Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Mol Biosyst 2016;12:3666-73. [PMID: 27731877 DOI: 10.1039/c6mb00610h] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 716 |
Hefferon K. Reconceptualizing cancer immunotherapy based on plant production systems. Future Sci OA 2017;3:FSO217. [PMID: 28884013 DOI: 10.4155/fsoa-2017-0018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 717 |
Nováková L, Pavlík J, Chrenková L, Martinec O, Červený L. Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. J Pharm Biomed Anal 2018;147:378-99. [PMID: 29031512 DOI: 10.1016/j.jpba.2017.07.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 718 |
Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infect Dis Ther 2017;6:423-33. [PMID: 28677020 DOI: 10.1007/s40121-017-0163-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 719 |
Breitinger U, Farag NS, Ali NKM, Breitinger HA. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors. Biophys J 2016;110:2419-29. [PMID: 27276260 DOI: 10.1016/j.bpj.2016.04.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 720 |
Twagirumugabe T, Swaibu G, Bergström T, Walker TD, Gahutu JB, Norder H. Low prevalence of hepatitis C virus RNA in blood donors with anti-hepatitis C virus reactivity in Rwanda. Transfusion 2017;57:2420-32. [PMID: 28671283 DOI: 10.1111/trf.14204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 721 |
Zhou S, Cella E, Zhou W, Kong WH, Liu MQ, Liu PL, Ciccozzi M, Salemi M, Chen X. Population dynamics of hepatitis C virus subtypes in injecting drug users on methadone maintenance treatment in China associated with economic and health reform. J Viral Hepat 2017;24:551-60. [PMID: 28092412 DOI: 10.1111/jvh.12677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 722 |
Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-matias T, Lu W, Cohen DE, Feld JJ. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet Gastroenterology & Hepatology 2017;2:494-500. [DOI: 10.1016/s2468-1253(17)30071-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 723 |
Kunwar S, Devkota AR, Ghimire DKC, Adhikari P. A fixed-dose combination of ledipasvir and sofosbuvir ± ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis. Drugs Ther Perspect 2017;33:348-360. [DOI: 10.1007/s40267-017-0401-2] [Reference Citation Analysis]
|
| 724 |
Tavares RCF, Feldner ACCA, Pinho JRR, Uehara SNO, Emori CT, Carvalho-Filho RJ, Silva ISS, Santana RAF, de Castro VFD, Castoli GTF, Cristovão CU, Ferraz MLCG. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2017;29:754-8. [PMID: 28234637 DOI: 10.1097/MEG.0000000000000866] [Reference Citation Analysis]
|
| 725 |
Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child 2017;102:668-71. [PMID: 28473309 DOI: 10.1136/archdischild-2017-312708] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 726 |
Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis 2017;49:731-41. [PMID: 28456519 DOI: 10.1016/j.dld.2017.03.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 727 |
Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VW, Wong GL, Nguyen MH. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. Am J Gastroenterol 2017;112:1111-9. [PMID: 28440303 DOI: 10.1038/ajg.2017.123] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 728 |
Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. Antimicrob Agents Chemother 2017;61:e00363-17. [PMID: 28416549 DOI: 10.1128/AAC.00363-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 729 |
Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. Int J Drug Policy 2017;47:144-52. [PMID: 28652072 DOI: 10.1016/j.drugpo.2017.05.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 730 |
Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 731 |
Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. J Med Chem 2017;60:5699-716. [PMID: 28594175 DOI: 10.1021/acs.jmedchem.7b00426] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 732 |
Abdurakhmanov E, Øie Solbak S, Danielson UH. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses 2017;9:E151. [PMID: 28621755 DOI: 10.3390/v9060151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 733 |
Lavie M, Dubuisson J. Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly. Biochimie 2017;141:62-9. [PMID: 28630011 DOI: 10.1016/j.biochi.2017.06.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 734 |
Wu Q, Li Z, Mellor P, Zhou Y, Anderson DH, Liu Q. The role of PTEN - HCV core interaction in hepatitis C virus replication. Sci Rep 2017;7:3695. [PMID: 28623358 DOI: 10.1038/s41598-017-03052-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 735 |
Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiol Infect 2016;144:1634-40. [PMID: 27125573 DOI: 10.1017/S0950268815003064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 736 |
Zheng BZ, D'Andrea SV, Hanumegowda U, Knipe JO, Mosure K, Zhuo X, Lemm JA, Liu M, Rigat KL, Wang YK, Fang H, Poronsky C, Cutrone J, Wu DR, Arunachalam PN, Balapragalathan TJ, Arumugam A, Mathur A, Meanwell NA, Gao M, Roberts SB, Kadow JF. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2017;27:3294-300. [PMID: 28633899 DOI: 10.1016/j.bmcl.2017.06.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 737 |
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 738 |
Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol 2017;15:945-949.e1. [PMID: 28238958 DOI: 10.1016/j.cgh.2017.02.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 739 |
El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said El Raziky M. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: Systematic review and meta-analysis. Arab J Gastroenterol 2017;18:51-7. [PMID: 28579340 DOI: 10.1016/j.ajg.2017.05.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 740 |
Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology 2017;65:1803-9. [PMID: 28220512 DOI: 10.1002/hep.29130] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 741 |
Khalil AT, Ali M, Tanveer F, Ovais M, Idrees M, Shinwari ZK, Hollenbeck JE. Emerging Viral Infections in Pakistan: Issues, Concerns, and Future Prospects. Health Security 2017;15:268-81. [DOI: 10.1089/hs.2016.0072] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 742 |
Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol 2017;66:1138-48. [PMID: 28189751 DOI: 10.1016/j.jhep.2017.01.028] [Cited by in Crossref: 136] [Cited by in F6Publishing: 142] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 743 |
Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore) 2017;96:e6984. [PMID: 28562549 DOI: 10.1097/MD.0000000000006984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 744 |
Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L Jr, Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R, Kumada H. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Adv Ther 2017;34:1449-65. [PMID: 28536999 DOI: 10.1007/s12325-017-0506-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 745 |
Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 746 |
Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2017;11:559-67. [PMID: 28317409 DOI: 10.1080/17474124.2017.1309284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 747 |
Abou Rached A, Yaghi C, Khalil L, Saba J, Ammar W. Prevalence of hepatitis C virus genotypes and subtypes in Lebanese population and major high risk groups. Arab J Gastroenterol 2017;18:114-7. [PMID: 28579342 DOI: 10.1016/j.ajg.2017.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 748 |
Kałużna E. microRNA-155 and microRNA-196b in Hepatitis C Virus Infection. In: Patel VB, Preedy VR, editors. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2017. pp. 809-36. [DOI: 10.1007/978-94-007-7675-3_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 749 |
Indolfi G, Thorne C, El Sayed MH, Giaquinto C, Gonzalez-Peralta RP. The Challenge of Treating Children With Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr 2017;64:851-4. [PMID: 28362694 DOI: 10.1097/MPG.0000000000001589] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 750 |
Jiao X, Fan Z, Chen H, He P, Li Y, Zhang Q, Ke C. Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. J Med Virol 2017;89:1597-605. [DOI: 10.1002/jmv.24829] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 751 |
Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ 2017;20:740-8. [PMID: 28489467 DOI: 10.1080/13696998.2017.1325744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 752 |
Forde KA, Bhattacharya D. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. Curr Treat Options Infect Dis 2017;9:262-76. [PMID: 29805320 DOI: 10.1007/s40506-017-0124-x] [Cited by in |
